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ABSTRACT OF THE THESIS
CONSTRUCTION AND SCREENING OF A cDNA LIBRARY FOR THE C3 GENE(S)
OF THE NURSE SHARK (GINGLYMOSTOMA CIRRATUM)
by
Janette Cristina Builes
Florida International University, 2001
Miami, Florida
Professor Sylvia L. Smith, Major Professor
Mammalian C3 is a complement protein which consists of an a chain (125kDa)
and P chain (75kDa) held together by a disulfide bond. The a chain contains a conserved
thiolester site which provides the molecule with opsonic properties. The protein is
synthesized as a single pro-C3 molecule which is post-translationally modified. C3 genes
have been identified in organisms from different phyla, however, the shark C3 gene
remains to be cloned. Sequence data from the shark will contribute to understanding
further the evolution of this key protein. To obtain additional sequence data for shark C3
genes a cDNA library was constructed and screened with a DIG-labeled C3 probe. Fifty
clones were isolated and sequenced. Analysis identified four sequences that yielded
positive alignments with C3 of a variety of organisms including human C3. Deduced
amino acid sequence analysis confirmed a P/a cut site (RRRR), the CR3 and properdin
binding sites, the catalytic histidine, and the reactive thiolester sequence. In the shark
there are at least two C3-like genes as the gene sequence obtained is distinct from that
previously described.
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I. Introduction
The complement system is an important recognition and effector system of innate
immunity (Jensen, et al., 1968; Day, et al., 1970; Reid, et al., 1981; Muler-Eberhard, et
al., 1988). It is made up of several serum components that work in a series of reactions to
attack invading pathogens. Components of the complement activation pathways are
illustrated in figure 1. The third component (C3) is pivotal as it is central to the
alternative, classical, and lectin pathways of complement activation. C3, along with C4,
are the thiolester containing complement proteins that are genetically related to each
other and to C5. All three proteins are believed to have evolved from a primitive a-2
macroglobulin-like molecule (Sottrup-Jensen, et al., 1985; Liszewski and Atkinson,
1993). C3 is synthesized as a single chain pro-C3 which is post-translationally modified
to a 190-kD glycoprotein that consists of two disulfide-linked chains known as the a and
p chains. The a chain contains a highly conserved thiolester site which provides the
molecule with opsonic properties. C3, upon activation by C3 convertases, is cleaved into
two fragments, C3a and C3b (figure 1). Both fragments have several important roles in
immune defense. C3b can: (a) opsonize invading pathogens, (b) mediate phagocytosis,
(c) bind B cells bearing CR1 receptor, and (d) bind to C4bC2a or C3bBb Classical
Complement Pathway or Alternative Complement Pathway C3 convertases to form C5
convertase of the classical/lectin pathways or alternative pathway, respectively. C3a is a
chemotactic and anaphylactic peptide. Studying the complement system of the nurse
shark (a primitive elasmobranch) can help us understand how complement systems have
evolved and their role as an immune modulator. Whereas mammals have a single C3
molecule, in lower vertebrates multiple isoforms of the molecule exist (Sunyer and Tort,
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Figure 1. Schematic illustration of the classical, lectin and alternative complement activation pathways
(see text for details) (bold straight arrows). Reactions catalyzed by serine proteases denoted by open
arrows. Cleavage fragments of activated components shown by curved arrows.
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et al., 1997; Nakao and Yano, 1998; Zarkadis, et al., 2001;) encoded by several genes.
As C3 is a pivotal protein, this study proposes to focus on this component alone.
Previous studies have yielded partial sequences for C3 homologues in the shark (Dodds
and Smith, 1998; Lee, 1999). While only one biologically active form of the protein has
been isolated from shark serum, gene cloning studies have yielded two partial cDNA
clones which are 68% similar in deduced amino acid sequence indicating that in the shark
at least two C3 genes exist. Furthermore, it appears, from earlier studies that one
sequence, NsC31 lacks the catalytic histidine at position 1126 and in its place is a
tyrosine (Lee, 1999). To understand the immunobiology of this molecule, it is necessary
to obtain additional sequence data. The aim of the study is to construct and screen a
cDNA library for clones that will provide additional nucelotide sequence data. The
experimental approach will include (a) construction of a cDNA library, (b) screening of
the library with a Digoxigenin labeled probe prepared from partial C3 cDNA clone
(C3A4), and (c) isolation and sequencing of positive C3 clones. The sequence data
obtained will permit phylogenetic analysis.
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II. Background
The Mammalian Complement System
The mammalian complement system is defined as several plasma proteins that act
in a series of coordinated reactions to bring about lysis and/or opsonization of pathogens
(Bokisch, et al., 1969; Muller-Eberhard, et al., 1988). Three activation pathways exist in
mammals (figure 1) that can be initiated in different ways, they are: the classical
complement pathway (CCP) (Muller-Eberhard, et al., 1966; Muller-Eberhard, 1975), the
lectin pathway (Sato, et al., 1994), and the alternative complement pathway (ACP)
(Medicus, et al., 1976; Liszewski and Atkinson, 1993). The classical pathway can be
activated by antigen-antibody complexes. The lectin pathway, which is considered to be
the most primitive was, however, the most recent to be described. This pathway is
initiated by the binding of a serum lectin, the mannan-binding lectin (MBL), to mannose-
containing proteins or carbohydrates present on the surface of bacteria or viruses. The
alternative pathway is not activated by antigen-antibody complexes, but rather it can be
spontaneously activated by interaction with pathogens of microbial origin or complex
molecules such as lipopolysaccharides, zymosan, nucleic acids, etc. The alternative
pathway is normally in a low level state of activation in serum where it is activated by
hydrolysis of the thioester bond of C3 leading to the formation of C3(H 20), a C3b-like
molecule. The three activation pathways lead to the formation of a C5 convertase
(C4b2aC3b, C3bBbC3b) that initiates the terminal lytic pathway by cleaving C5 and
activating C6 through C9 to form the Membrane Attack Complex (MAC) which, when
inserted into membranes, brings about cell lysis (Green, et al., 1969; Humphrey, et al,
1969; Gotze, et al., 1970; Pangburn, et al., 1980; Bhakdi, 1983; Muller-Eberhard, 1986).
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Thus, complement activation can be described as a cascade of reactions that includes
proteolytic cleavage of some of the components with binding of activation fragments to
other complement molecules forming multimolecular enzymatic complexes that bind to
targets, bringing about lysis or opsonization.
The Classical Pathway of Complement Activation
The classical complement pathway involves four complement components that
interact in a series of reactions to produce the classical pathway, they are in order of
reaction sequence: C1, C4, C2, and C3. C1 is a calcium dependent multimeric complex
with a molecular mass of 750 kD consisting of a single C1q molecule and associated
serine protease tetramer, Cl s-Cl r-C 1 r-C 1s. Cl q has 18 polypeptide chains of three
distinct types organized in a complex that resembles a bouquet of flowers. Clq binds to
the Fc portion of antibody (a single molecule of IgM or two or more IgG molecules)
bound to antigen complexes. IgM is more efficient than IgG in binding to Cl q since only
IgM one may be enough for binding. After binding to antibody Cl q undergoes a
conformational change which leads to the activation of the C is-Cl r-C 1 r-C is tetramer.
Activated C is is an active serine protease that first cleaves the cc-chain of C4 generating
C4a and C4b, and then cleaves C2, which is a single polypeptide chain of 117 kD, when
it associates with C4b to generate C2a and C2b with the formation of C3 convertase
(C4bC2a) of the classical pathway. C4 is a 200 kD protein composed of three peptide
chains (a, P, and y) linked together by disulfide bonds and containing a thiolester bond in
its a chain.
C4b when activated binds covalently to a target surface via its thioester and acts
as an opsonin. The C4bC2a enzymatic complex when formed remains bound to the
5
activating surface. If C4b does not bind as an opsonin or associate to form the convertase
it is further cleaved by factor I and inactivated (iC4b) (Fearon, et al., 1977). C4b2a (C3
convertase) can cleave C3 leading to the generation of C3a and C3b. C3 is a 190 kDa
protein made up of a 115 kDa a chain and an 75kD P chain linked together by disulfide
bonds. The smaller fragment cleaved from C3 is C3a which is a moderately potent
anaphylatoxin. The larger fragment is the metastable protein C3b that has the transient
ability to attach covalently via its thioester bond to a nearby substrate via hydroxyl (OH)
or amide (NH 2) groups. This membrane-bound C3b serves three different purposes: as
an opsonin to facilitate phagocytosis by C3b receptor-bearing host cells, to associate with
C4b2b to form the C5 convertase of CCP (C4b2aC3b), or to associate with factor B and
trigger the alternative pathway of complement activation.
The C5 covertase (C4bC2bC3b) cleaves C5 which is a 190 kDa disulfide-linked
heterodimer with homology to C3 and C4 but lacking an internal thioester bond in its a
chain. Cleavage of C5 forms the potent anaphylatoxin, C5a, and the larger fragment C5b
that remains close to the convertase on the microbial surface, thus inititating the assembly
of the membrane attack complex (MAC) (Lambris, 1988).
The Lectin Pathway
As stated earlier, activation of this pathway occurs by the binding of mannans to
the mannose-binding lectin (MBL) associated with two serine proteases known as the
MBL-associated serum proteases (MASP). The MASP cleaves C4 and/or C3 to form C3
convertase. There are three isotypes of MASP: MASP-1, MASP-2, and MASP-3.
MASP-1 cleaves C3 but not C4, whereas, MASP-2 cleaves C4 (Fishelson, 1991 ). When
C3 is cleaved by the MASP it leads to amplification via the alternative pathway.
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The Alternative Pathway
Initiation of the alternative pathway is unlike the previous two pathways
described. Four plasma proteins are directly involved in the alternative pathway: C3,
factors B and D, and properdin. The alternative pathway is also not antibody dependent,
yet the presence of antibody aggregates can enhance its activation (Fishelson, 1991).
This pathway can be directly activated by microorganisms or complex polymers, or
indirectly via the Lectin Pathway described above. The alternative pathway is usually at
a low level of constant activation since in serum the thioester bond of native C3 can be
hydrolysed by water forming C3(H 2O) which structurally resembles C3b but is lacking an
active attachment site. C3(H 2O) in the presence of appropriate activators can bind to
Factor B in the fluid phase. Factor B is a single-chain, 93 kDa serine protease precursor.
The binding of factor B to C3(H 20) or C3b allows Factor D, a 25 kDa plasma serine
protease, to cleave factor B at the single arginine-lysine bond releasing the small
fragment Ba and leaving the larger Bb fragment attached to C3(H 20) forming the initial
fluid phase C3 convertase of the alternative pathway. This, in turn, cleaves additional
molecules of C3, producing C3b that associates with factor B which is further cleaved to
form the C3 convertase of the alternative pathway (C3bBb). C3bBb is labile but can be
stabilized by the binding of properdin to the complex. Properdin is a 220 kD stabilizing
tetrameric protein that extends the half-life of the convertase six to 10-fold by the
membrane bound C3 convertase, C3bBb. C3bBb associates with a second molecule of
C3b to form the C5 convertase (C3bBb3b) of the alternative pathwawy. This, in turn,
cleaves C5, thereby initiating the terminal lytic pathway and the formation of the MAC.
As an opsonin, C3b binds to activation surfaces via ester or amide linkages through the
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thiolester bond. In the absense of such a reaction, C3b is inactivated by factor I (a serine
protease) cleavage in the presence of regulatory molecules such as complement receptor
1 (CR1), factor H, membrane cofactor protein (MCP), and delay accelerating factor
(DAF).
The Terminal Lytic Pathway
All three pathways lead to the terminal effector lytic pathway which involves the
formation of the Membrane Attack Complex (MAC) (Green, et al., 1959; Humphrey, et
al., 1969; Gotze, et al., 1970; Pangburn, et al., 1980; Bhakdi, 1983; Muller-Eberhard,
1986); The assembly of MAC involves activation of C6 through C9. Activation of these
components, however, does not involve proteolytic cleavage of the proteins but rather
confromational change, association and polymerization. C5b bound to target surfaces
binds to C6, a 128 kDa single-chain protein which further binds C7, a 121 kDa single-
chain protein (Lachmann, 1970; Arroyare, et al., 1973; Muller-Eberhard, 1975). C7 gives
liphophilicity and membrane attachment capabilities to the complex formation. The
C5b67 complex acts as a high-affinity membrane receptor for a C8 molecule (a 155 kDa
trimer). The final stage of assembly consists of polymerization of C9, a 79 kD
monomeric protein, that binds to the C5b-8 complex. Polymerization and insertion of C9
molecules forms transmembrane channels (holes) with subsequent lysis of target (Gotze,
et al. 1970; Lachmann, et al., 1970; Kolbet, et al., 1972).
The different mechanisms by which the complement system can be activated has
allowed the complement system to efficiently handle the invasion of pathogens and to
mount an effective inflammatory response. The key step in complement activation is the
formation of C3 and C5 convertases which cleave C3 and C5 at identical cut sites on the
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a chain to generate fragments C3a and C3b, C5a and C5b, respectively. The end result
of complement activation is the lysis and removal of pathogens or target cells.
Components such a C3a, C4a, and C5a act as peptide mediators of inflammation and
phagocyte recruitment (chemotaxis). These three components are small fragments
known as anaphylatoxins. Anaphlyatoxins induce a systemic inflammatory response that
includes increase of vascular permeability, smooth muscle contraction, and chemotactic
migration of inflammatory cells to the site of antigen activator deposit. Additionally,
anaphylatoxins bind to receptors on the surfaces of mast cells and basophils to elicit the
release of vasoactive compounds such as histamine and serotonin. Activation of
complement also modulates the adaptive immune response via the activity of these active
fragments generated from C3, C4, and C5.
The Biological Role of C3
Mammalian C3 has been thoroughly studied and much is known about its
structure and biological function. In humans, C3 is the most abundant complement
protein in serum (1.2mg/mL). It is the most versatile and multifunctional molecule of
the complement system. More than 20 soluble and membrane bound proteins interact
with C3 (Lamris, 1998). The C3 molecule is a glycoprotein composed of a 115 kDa a
chain and a 75 kDa P chain, held together by a single disulfide bond (figure 2b). The 3D
structure consists of two domains, a flat ellipsoid domain associated with a flat domain
(Whitehead, et al., 1982).
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(a)
Pro-C3
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H2N COOH
convertase cleavage site Native C3
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Figure 2. Molecular structure of pro-C3, native C3, and C3b. (a) Pro-C3 protein shown
as a single chain with a D/a cut-site and thiolester site. (b) Native C3 following post
translational modification of the single chain pro-C3 into the two-chain C3 structure
composed of the a and 0 chains held together by an interchain disulfide bond. The site
of activation of cleavage by C3 convertase is indicated by an arrow. (c) C3 cleavage
products, C3a and C3b.
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The activation of native C3 occurs by C3 convertase cleavage between the 77 and
78 (Arg-Ser) amino acid residues of the a chain. The released N-terminal fragment
(C3a) is a small 77 amino acid residue peptide which is an anaphylatoxin (figure 2c).
C3a consists of five carboxy-terminal amino acids that elicit the diverse biological effects
on target cells. The cellular interaction is believed to be via a specific C3a receptor as not
all cells respond to C3a. The large C3b fragment, made up of the a chain and the
complete P chain, is also biologically active (figure 2c). It interacts with other
complement components to produce enzymatic complexes, and is a major opsonic
molecule that facilitates phagocytosis of target cells. C3b interacts with different cell
receptors such as complement receptor type 1 (CR1), and can be further degraded by
various control proteins (factor I, factor H) which regulate its activity.
Inactivation of C3b is brought about by the enzymatic activity of factor I in the
presence of cofactors such as factor H in the ACP or C4b in the CCP. Factor I cleavage
yields the inactive form, iC3b, by the excision of a 2 kDa peptide (C3f) between residues
1281-1282 (Arg-Ser) and 1298-1299 (Arg-Ser) (Lambris, 1998). A second factor I
cleavage occurs at residues 932 and 933 (Arg-Glu) resulting in the release of C3dg while
C3c remains bound to the target surface. C3dg can be degraded further with trypsin,
elastase, or plasmin producing C3g (for review Lambris, et al., 1986). The various
activation fragments of C3, i.e. C3b, iC3b, C3c, C3dg, C3c and C3g are all capable of
further interaction with a variety of soluble and cell bound molecules that modulate the
immune system (for review Fishelson, 1991; Lambris, 1988). C3a through binding to the
C3a receptor (C3aR) can induce several cellular responses in cells expressing the
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receptor, such as mast cells, neutrophils, monocytes, basophils, and macrophages (for
review Lambris, 1988).
C3 Binding Sites
C3b has several different binding sites: the thiolester site is present in the a chain
between amino acid residues 1010 and 1013 (Cys and Gln). In native C3, the thioester is
inaccessible and buried inside the C3 molecule. Upon cleavage by C3 convertase and the
release of C3a, a conformational change occurs that exposes the reactive thioester bond
which can react with the amine (-NH 2) and hydroxyl (-OH) groups present on proteins
and carbohydrates of targets, or alternatively the thiolester bond can be hydrolysed with
water (Wetsel, et al., 1984; Fishelson, 1991, Dodds, et al., 1996). If a transacylation
reaction occurs, the thioester bond covalently attaches the molecule to the surface of
targets via amide or ester groups (Fishelson, 1991). When C3b binds to an activator
surface, three things may occur: 1) surface-bound C3b behaves like an opsonin and
mediates the phagocytosis of the target by polymorphonuclear leukocytes, monocytes,
and macrophages bearing Complement Receptor Type 1 (CR1) receptors; 2) B-cells
bearing CR1 receptors are activated; or 3) the covalently attached C3b forms the C5
convertase of either pathway (Sunyer, et al., 1997).
C3b has multiple binding sites for C5, properdin, factor H, factor B, factor I, C4
binding protein (C4bp), CR1, and the membrane cofactor protein (MCP). C3b can also
interact with laminin, fibronectin, Herpes Simplex Virus gpC, Epstein-Barr Virus (EBV),
and IL-2. The binding site for C5 has been localized to the P chain of C3b and it is the
only ligand found to bind to the P chain of C3. Properdin binds to the C3bBb convertase
and acts to stabilize the complex and to regulate the alternative pathway (Fearon, et al.,
12
1977; Reid, et al., 1986). The properdin binding site lies between residues 1402-1435 of
C3 (Lambris, et al., 1986; Lambris, 1988; Fishelson, 1991).
Factor H competes with factor B binding for a site on C3b, and serves as a
cofactor for factor I mediated cleavage of C3b (Fearon, 1977; Reid, 1986; Lambris, et al.,
1986; Lambris, 1988; Fishelson, 1991). The C3 molecule has several binding sites for
Factor H. One binding site on the a chain for factor H has been localized to the amino
acid region between 745-754 which overlaps the binding region for CR1 (residues 749-
790) (Fishelson, 1991). Two other sites for factor H binding can be found within the C3c
region of C3b between 1209-1271 and one site has been identified as being discontinuous
within the C3d region of residues 1187-1249 (Lambris, et al., 1986).
C3b binds factor B at a site between 749-790. The initial binding of factor B to
C3(H20) occurs within the Ba region of factor B allowing it to be cleaved. Bb remains
attached to C3(H20) and Ba is released. The C3(H20)Bb complex is the initial C3
convertase in the alternative pathway when additional molecules of C3 are cleaved.
Factor B binds to C3b in the presence of magnesium ions to form the ACP C3 convertase
after it is cleaved by factor D. The convertase is stabilized by properdin (Lambris, et al.,
1986; Fishelson, 1991). It is believed that C3b may have two sites for binding factor B.
One site in C3b has been located to be within amino acid residues 730-739 (Lambris, et
al., 1986) and it has also been postulated that the Bb region of factor B may be within the
C3d region (residues 933-942) (Lambris, et al., 1986). Although, the binding site for
factor I has not been identified it appears that it can associates with C3b-H and thus close
to binding sites for Factor H, CR1 and CR2 (Lambris, et al., 1986; Fishelson, 1991).
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C3 Genetics
C3 is a member of a group of thiolester proteins which include C4, C5, and a
noncomplement protein, a-2 macroglobulin (x2MAC) (Swenson, et al., 1979; Howard,
et al., 1980; Tacket, 1980; Campbell, et al., 1981). These components are believed to
have arisen from an ancestral primordial gene by gene duplication (Sim, et al., 1981;
Starkey, 1981; Sottrup-Jensen, et al., 1985; Nonaka, et al., 1992; Nonaka, et al., 1998).
While C3, C4, and C5 share sequence homology they differ in their subunit structure. C3
and C5 are 2 chain molecules while C4 is a 3 chain molecule. C3 resembles C5 in
subunit structure but the latter lacks the thiolester bond. All (including a-2
macroglobulin), however, arise from single genes and the single transcript yields the pro-
protein which is post-translationally modified (Brade, et al., 1977; Hall and Colten, 1977;
Swenson, 1980).
While the loci of complement components factor B, C2 and C4 are closely linked
to the HLA-B locus on chromosome 6, the human C3 gene has been mapped outside the
HLA-B region on chromosome 6 and has been mapped to chromosome 19. Family
studies show that C3 is linked to the Lewis blood group that happens to be linked to
myotonic dystrophy present on chromosome 19. Allelic variants of C3 do exist, but to
date the number present in the human genome is unknown (Whitehead, et al., 1982).
The C3 gene contains 41 exons that range in size from 52 to 213 base pairs.
Introns, which are spliced out during mRNA processing, range in length from 82 to 4400
base pairs. Human C3 gene intron sequences have the 5' and 3' splice donor and
acceptor sequences followed by the usual GT/AG pattern. The transcription initiation
sites are localized to two positions at 61 and 63 residues 5' from the start codon ATG.
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TATA and CAAT boxes have been identified at -28 and -87 base positions respectively.
The stop codon, TGA, is found at position 5050 and the poly-(A) tail at position 5077
(Vik, et al., 1991). Genomic DNA encoding human C3 produces a mRNA transcript
molecule that codes for 1663 amino acid residues, prepro-C3 (Vik, et al., 1991).
C3 of Nonmammalian Species
C3-like molecules have been identified in the different species. C3 homologues
or C3-like proteins have been reported in invertebrate species (Smith, et al., 1996; Al-
Sharif, et al., 1998) and vertebrates in which complement or complement-like activity has
been demonstrated (Sunyer, et al., 1980; Nonaka, 1981). In these organisms, C3 gene
arrangement or protein structure is not identical, however, each possesses highly
conserved sequences within the genes. One such conserved sequence is the thiolester
bond sequence. Interestingly, the thioester bond is also present in the protease inhibitor
a-2 macroglobulin (a2Mac), which is not considered a complement related protein
(Wetsel, et al., 1984; Nonaka, et al., 1992).
C3 related molecules have been described in invertebrate species. The first C3-
like protein to be identified in an invertebrate was a molecule designated SpC3 expressed
in the purple sea urchin, Strongylocentrotus purpuratus (Smith, et al., 1996; Al-Sharif, et
al., 1998). Until recently, this was thought to be the most ancient invertebrate C3-like
molecule, however recent studies have identified a C3 sequence in the coral (Dishaw,
unpublished data).
C3 homologous proteins have been described for several vertebrate phyla,
including two agnathan cyclostomes considered to be th the most primitive vertebrates,
the hagfish and lamprey. The hagfish (Eptatretus burgeri) C3 is a thioester-containing
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protein that behaves like an opsonin, but interestingly has a three-chain structure after
proteolytic cleavage of an irregular two-chain C3 structure made up of an a + y chain and
a P chain (Ishiguro, et al., 1992; Hanley, et al., 1992; Fujii, et al., 1995). Homology to
human C3, and C4 was 30.5% and 27.9% respectively. This may imply that the hagfish
C3 may have similar properties to both C3 and C4 of humans, but more so of C3
(Ishiguro, et al., 1992). Lamprey, Lampreta japonica, C3 is similar in subunit structure
to mammalian C4 as it is a three-chain structure (containing a, p3, and y chains), yet its
homology is highest with C3. Lamprey C3 does not mediate target cell lysis, but acts as
a phagocytic factor. It has been proposed by Nonaka (1992) that the lamprey C3 may be
the common ancestral molecule of C3, C4, and C5 in that C4 diverged from a three-chain
C3, C3 lost the a-y junction region becoming a two-subunit structure, and C5 diverged
from a two-chain C3 and lost the thiolester bond (Nonaka, et al., 1984; Nonaka, et al.,
1992)
Several isoforms of C3 have been reported for certain species of teleost (bony) fish
(Nonaka and Yamaguchi, et al., 1981; Nonaka and Sakai, et al., 1981; Lambris, et al.,
1993; Sunyer, et al., 1997; Nakao, et al., 2000; Zarkadis, et al., 2001). Four isoforms of
C3 have been found in the rainbow trout and designated as C3-1, C3-2, C3-3, and C3-4,
of which only three (C3-1, C3-3, and C3-4) are functional (Nonaka, et al., 1981; Lambris,
et al., 1993; Sunyer, et al., 1996). These four isoforms differ in amino acid sequence
identity and in their binding to complement activators and may be encoded by two
different C3 genes (Lambris, et al., 1993; Nonaka, et al., 1998; Sunyer, et al., 1996;
Zarkadis, et al., 2001). The common carp (Cyprinus carp) has been found to have five
types of C3 known as C3-S, C3-Q1, C3-Q2, C3-H1, and C3-H2 (Nakao, et al., 2000) Of
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these five types, C3-S, C3-Q1, and C3-Q2 are missing the catalytic histidine which is
conserved in C3 of most animals analyzed to date and provides the thiolester with the
ability to bind covalently to hydroxyl groups on target cells or to be hydrolized quickly.
Although, these variants in the carp were missing the catalytic Histidine, some
demonstrated high hemolytic activity suggesting that the thiolester's catalytic mechanism
is not a determinant of C3 activity and molecules lacking the catalytic histidine play a
functional role in the carp (Nakao, et al., 2000). The trout and the carp are tetraploids,
which might explain the presence of different isoforms (Sunyer, 1996; Nakao, et al.,
2000; Zarkadis, et al., 2001). It has been suggested that the C3 isoforms in trout and the
carp increase the number of possible pathogens that can be recognized and thus enhance
the protective effect of complement.
Another telost is the gilthead sea bream, Sparus aurata, which is a diploid and
was also found to contain five isoforms of C3 (Sunyer, et al., 1997; Sunyer, et al., 1997).
The sea bream C3s are believed to have evolved from the trout C3s and it is likely that
one or more of the C3s may have duplicated, thus producing the five isoforms. The five
isoforms in the sea bream have remained functional (Sunyer, et al., 1980; Sunyer, et al.,
1997). These five isoforms in the seabream also increase the performance of their
immune system since their specific immune response to pathogens based only on
immunoglobulin M is a later response and not immediate (Sunyer, et al., 1997).
The reptile complement system has been studied in the cobra, Naja naja kaouthia.
The C3 gene in the cobra encodes for a two-chain protein with an internal thioester and
high homology with C3 molecules of other vertebrates (Fritzinger, et al., 1992). Three
additional C3-related genes have been found in the cobra. The product of one of these
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genes was found in the venom of the cobra and has been named Cobra Venom Factor
(CVF) (Fritzinger, et al., 1994). CVF is a complement activating protein and is
functionally related to C3b in that it is able to associate with factor B and form a C3bBb-
like convertase in the presence of factor B and D. The molecular structure of CVF is
different from its complement component C3 in that it is composed of three chains and
does not have a thioester site in the a chain. Two other mRNA transcripts have been
identified in the cobra and found to be 90% homologous to cobra C3, as was CVF
(Fritzinger, et al., 1992; Sunyer, et al., 1998).
In aves, C3 has been identified in the chicken and japanese quail (Kai, et al.,
1983; Mavrodis, et al., 1995). Chicken C3 has 54% identity to human and has a two-
chain structure similar to humans (Mavroidis, et al., 1995). The Japanese quail C3 was
also found to resemble human C3 and to function as complement component C3 (Kai, et
al., 1983). The murine C3 has also been identified and its P and a chain structures have
high identity to human C3 P and a chains, 73% and 75%, respectively.
C3 in the Nurse Shark
C3 molecules have been described for the elasmobranch, Ginglymostoma
cirratum. The N-terminal amino acid sequence of nurse shark C3 a and P chains display
28% and 50% homology with corresponding chains of human C3 (Dodds, et al., 1998).
Previous studies in the nurse shark yielded two related, but distinct partial C3 clones,
C3A4 (figure 3) and C3A7, which suggested that there may be more than one isoform of
C3 in the nurse shark although only one functional C3 protein was isolated from shark
serum (Dodds & Smith, 1998; Nonaka & Smith,). The two C3-like cDNA clones (Nakao
& Smith, unpublished data) were used to design gene specific primers for 3' and 5' Rapid
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Amplification of cDNA Ends (RACE) PCR. Several RACE products ranging in size
from 800kb to 1800bp were generated. Deduced amino acid sequence generated from a
1800bp (NsC31) 3' RACE product clone showed the absence of the conserved catalytic
histidine residue at position 1126 (Lee, 1999). As this residue is essential for optimal
function of the thiolester, it is possbile that the clone, represents sequence of a
nonfunctional C3 protein since catalytic histidine is believed to be essential for thiolester
binding to hydroxyl groups. This 3' RACE product was generated from gene specific
primers designed from the sequence of clone C3A7. This observation suggests that as the
two partial clones, C3A4 and C3A7, represent two genes encoding two different isoforms
of C3 in the shark, and C3A7 represents a C3 gene which encodes a protein missing the
critical histidine, then C3A4 must code for the functional protein that has been isolated
from shark serum. To confirm this hypothesis the construction and screening of a cDNA
library for C3 clones, using C3A4 as a probe, will provide additional gene sequence data
that can determine the number of C3 isoforms in the nurse shark. Analysis of amino acid
sequence data will also provide information on the biological significance of a C3-like
molecule which lacks a catalytic histidine residue.
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III. Materials and Methods
RNA Isolation from Nurse Shark Liver
Approximately 2.5g of liver from a nurse shark, Ginglymostoma cirratum, was
added to 25ml of TRIzol (GibcoBRL Life Technologies). The sample was homogenized
for 1 minute using a homogenizer. The homogenized sample was placed on ice and 0.2
ml of chloroform per 1 ml of Trizol was added to the mixture, which was shaken
vigorously for 45 seconds and incubated for 3 minutes at 25 C. The mixture was
centrifuged at 3220xg for 40 minutes at 5*C, and the aqueous phase was withdrawn and
transferred to a fresh tube. The RNA was precipitated from the aqueous mixture by
adding isopropanol (0.5ml of Isopropyl alcohol per lmL of Trizol). Sample was mixed
gently, incubated at 25 C for 10 minutes and centrifuged at 3220xg for 40 minutes at
5 C. The RNA formed a gel like pellet after centrifugation. The supernatant was
removed and the pellet washed once with 75% ethanol. Sample was mixed by vortexing
for 5 seconds and centrifuged 3220xg for 20 minutes at 5 C. The supernatant was
discarded and the RNA pellet dried for 10 minutes. The dried RNA pellet was dissolved
in 250 pL of DEPC H20. A 500 fold dilution was made of the RNA sample and the
concentration and purity of the RNA sample was determined spectrophotometrically by
determining the OD 2 60/OD 2 80 ratio.
Electrophoretic Analysis of RNA
A 1% agarose gel in tris-borate/EDTA (TBE) was prepared by heating and dissolving 0.5
g of agarose in 50 mL of lx TBE. The agarose was allowed to cool before adding
ethidium bromide (10mg/ml stock solution) at a concentration of 0.5ug/ml. It was mixed
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thoroughly, and poured into the electrophoresis chamber containing the comb in place
and allowed to set for 45 minutes. Four 10 fold diutions of the RNA sample were mixed
with 6x Gel Loading Buffer in a final volume of 18pl. The agarose was emersed in lx
TBE and 12 l of sample RNA was loaded per well. An RNA standard was also run
which provides visible banding at the 28S and 18S rRNA with a smear ranging from
400bp to 8kb. Electrophoresis was carried out at a constant voltage (80 volts) and
terminated when the sample migrated passed the midpoint of the gel. The gel was stained
with ethidium bromide and visualized over an ultra violet lamp.
mRNA Isolation
The QuickPrep mRNA purification Kit (Amersham Pharmacia) was used to
isolate mRNA. Two samples of mRNA were prepared using 40 pl and 80 pl of total
nurse shark liver RNA (12pg/pl concentration) and labeled A and B, respectively. The
RNA was mixed with 1.5 ml of Extraction Buffer in a 15m1 tube and 3mL of Elution
Buffer was added to the extract and mixed throughly. Afterwards, the Elution Buffer was
warmed and maintaned at 65 C. An Oligo(dT)-Cellulose Spin Column was prepared
(one column per sample) and inverted several times to resuspend the contents. The top
and bottom closures of the column were removed and the column placed in a 15 mL
centrifuge tube. Together they were centrifuged at 350xg for 2 minutes. The column
was removed from the tube and the liquid remaining in the tube was discarded. The top
and bottom closures of the spin column were replaced securely before placing the column
upright in a rack. A portion (4mL) of RNA sample mixture was loaded onto the surface
of the resin of the spin column which was then inverted for 10 minutes and centrifuged at
350xg for 2 minutes. The top closure was removed and the supernatant was discarded.
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Three milliliters (3mL) of High Salt Buffer was applied to the top of the resin and after
replacing the top the matrix was resuspended by tapping on the tube. The column was
returned to the 15ml tube and together centrifuged at 350xg for 2 minutes. The
supernatant decanted and the High Salt Buffer wash was repeated twice and after the last
wash 3 mL of the Low Salt Buffer was applied to the column and the matrix resuspended.
The column was centrifuged as before and the supernatant decanted and discarded. After
removing the bottom closure of the column 3 mL of Low Salt Buffer was applied and the
column centrifuged at 350xg for 2 mintues. The spin column was removed and placed
into a fresh 15 mL tube and the bound poly(A)+-RNA was eluted with 250 L of Elution
Buffer prewarmed at 65*C. The column was centrifuged at 350xg for 2 minutes and the
eluted poly(A)+-RNA was collected and transferred to a microcentrifuge tube. Elution
with 250 pL of Elution Buffer was repeated two more times. At the end of the elution
step approximately 750 pL of poly(A)+-RNA had been isolated. The OD 26onm/2 8onm
readings of the poly(A)+-RNA preparation was measured to confirm the presence of
RNA.
cDNA Synthesis
First Strand Synthesis
The cDNASynthesisKit (Stratagene) was used to synthesize cDNA. Prior to
setting up the reaction all nonenzymatic first-strand components were thawed by placing
in a 37 C H20 bath. When completely thawed (approximately 40 minutes) each reagent
tube was briefly vortexed and the contents spun down before preparing a reaction mixture
of 50 pL (final volume) which contained 12.5 pL of reagents and enzymes and 37.5 pL
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of mRNA and DEPC water. A control was set up with a final volume 37.5 L that
contained 25 pL of test RNA and 12.5 pL of DEPC water. In a microcentrifuge tube on
ice the following reagents/ sample were added and mixed in the order listed:
lOx 1St strand buffer 5pL
1lt strand methylnucleotide mix 3 pL
linker primer (oligo dT) 2pL
RNAse Block Inhibitor 1 L
mRNA 5pg
DEPC H20 volume adjusted to obtain a
total volume of 50 L in the reaction mix
All sample reaction mixtures were mixed and spun down to collect contents. Equal
volumes (0.75 pL) of MMLV-Reverse Transcriptase (50U/ L) and Powerscript Reverse
Transcriptase (1 OOU/ L) were added to each reaction mixture and incublated for 30
minutes at 37 C and then placed on ice.
Second Strand Synthesis
The following reaction mixture was prepared:
lOx 2 "d Strand Buffer 20[L
2"d Strand dNTP mix 6pL
H20 111pL
RNAse H 2[L
Polymerase I 11 pL
Template (first-strand synthesis as above) 50 pL
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The contents were thoroughly mixed and incubated for 2.5 hours at 16 C. The
temperature was maintained by preparing an ice bath in a styrofoam box that was kept
constant at 16 C. The reaction mixtures were placed on ice after incubation and 23 pL
of Blunting dNTP mix was added to each, followed by 2 pL Pfu DNA Polymerase. The
reaction tubes were incubated for 30 seconds at 72 C and placed on ice. Only five (5) pL
of each sample was electropheresed on a 1% TAE gel and during electrophoresis 200 L
of PCI was added to the remaining contents in the sample reaction tubes and vortexed.
The samples were then centrifuged at 21,000 x g for 2 minutes at 25 C. The aqueous
phase was saved and 25 pL of 3M sodium acetate and 500 pL of ethanol was added to it.
Precipitation of cDNA was allowed to occur overnight at -20 C. Precipitated samples
were centrifuged at 15,000 rpm for one hour at 4 C. The supernatant was decanted and
the pellet washed with 70% ethanol, centrifuged at 21,000 x g for 2 minutes at 4*C, and
after decanting and discarding the supernatant, the pellet was dried at 37 C for 10
minutes. The pellet contained the cDNAs synthesized after second-strand synthesis.
Construction of cDNA Library
Ligating EcoRl Adapters
The cDNA pellet was resuspended in 8 pL of EcoRl Adapters and incubated for 30
minutes at 4 C. The following components were added to the cDNA tube containing the
EcoR1 Adapters and mixed:
1Ox Ligase Buffer 1 pL
1OmM nATP 1p L
T4 DNA Ligase (4U/pL) 1 pL
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The reaction tube was incubated overnight at 8 C in a cooling block. The ligase in the
reaction mixture was inactivated by placing the sample in a 70 C water bath for 30
minutes. The components were spun down and the reaction cooled for 5 minutes at
25 C. The Adapter Ends were phosphorylated by adding the following reagents mixed:
1Ox Ligase Buffer 1 L
10mM rATP 2 L
Sterile H20 6pL
T4 Polynucleotide Kinase (1 OU/pL) 1 pL
The reaction mixture was incubated for 30 minutes at 37 C. The kinase was heat
inactivated for 30 minutes at 70*C and components centrifuged and equilibrated to room
temperature for 5 minutes before digesting with XhoI by adding 28 L of XhoI Buffer
and 3pL of XhoI (40U/pL). The reaction mixture was incubated for 1.5 hours at 37 C.
The sample was precipitated by the addition of 5 L of lOx STE and 125 L of 100%
ethanol (w/v). Following precipitation the sample was centrifuged at maximum speed,
15,000 rpm for 15 minutes at 4*C. The supernatant was discarded and the pellet dried in
a 37 C incubator. The dried pellet was resuspended in 14[L of lx STE Buffer. Loading
dye (3.5pL) was added to the sample to determine size fractionation of digested sample
by chromatographic separation.
In order to proceed with size fractionation a drip column was assembled. A 3mL
syringe and a 21 2 gauge needle per sample was used. A small piece of sterile cotton
from a disposable glass pipet was cut in half so that it fit inside the syringe. The cotton
was tightly packed into the syringe. The Sepharose CL-2B Gel Filtration Medium and
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the 1Ox STE Buffer were equilibrated to room temperature. The lOx Stock of STE
Buffer was diluted in sterile H20 to prepare 50 mL of lx STE Buffer. The syringe with
the cotton plug was placed upright on a clamp. With a Pasteur pipette 2 mL of the 1x
STE Buffer was added to the cotton plug. The STE was allowed to drip through the
cotton plug and the flow through was disposed. Immediately, 2mL of the suspension of
Sepharose CL-2B was added to the syringe by inserting the tip of the Pasteur pipette as
far into the column as possibe. When the resin settled, the Sepharose was continuously
added until it was packed tightly and its height measured was equivalent to 1.2 mL in the
syringe. The drip column was washed three times with 1.2 mL of STE buffer to ensure
that the buffer flowed at a steady rate. The column was not permited to dry out. When 50
pL of STE buffer remained above the surface of the resin, the cDNA sample was
immediately loaded using an automatic pipettor. The sample was gently released onto
the surface of the column bed without disturbing the resin as it may affect the cDNA
separation. Once the sample had entered the sepharose, buffer was applied to the
column. Column fractions were collected in 20 microcentrifuge tubes until the dye front
reached close to the bottom of the syringe. Approximately, 400 pL (equivalent to 6
drops) of column eluate was collected per fraction. Collection of fractions was stopped
when drops from the column became clear, that is, drops did not contain traces of loading
dye. After fractionation, the cDNA in fractions was semi-quantitated by comparing its
UV intensity to a diluted DNA marker (GibcoBRL) of known concentrations. This was
accomplished by preparing six different dilutions of the marker: an initial 1/5 dilution in
H2 0 and then two fold (1/2) serial dilutions thereafter of the initial 1/5 diluted marker.
An estimation of cDNA concentration was obtained as follows. First a sheet of saran
27
wrap was placed on the surface of the UV light illuminator, then a row of 2 pL drops of
ethidium bromide ( 2 g/pL) was placed on the saran wrap. To each ethidium bromide
drop 2 L of a single dilution was added and mixed, similarily each cDNA fraction was
mixed with a 2 L drop of ethidium bromide. A photograph was taken of the drop mix to
determine whether and which fractions contained cDNA by observing the fluorescent
intensity of the ethidium bromide in the size fractionated cDNA samples. The cDNA
concentration of the samples was estimated by comparing fluorescence of sample to that
of known marker dilutions. Visualization of the samples in this manner allowed selection
of sample cDNA containing fractions that could be pooled. Also, the brighter the
ethidium bromide fluorescence, the larger or more cDNA fragments were present in the
fraction.
Agarose Gel Electrophoreis of Fractionated Samples
All fractions were electrophoresed and analyzed on a lx TBE, 1% TAE agarose
gel as follows: 5 pL of each sample fraction was mixed with 1 pL of 6x Gel Loading
Buffer and added to each well. Electrophoresis was carried out for 45 mintues at 80
Volts and the ethidium bromide stained gel was photographed. From comparison of the
fluorescence intensity of each sample fraction we could determine the presence of cDNA
smears and identify the sample fractions which could be pooled together, as brighter
fluoresecence intensity signaled the presence of more cDNAs. Samples selected to be
pooled together were all combined into one microcentrifuge tube and approximate
measurements of DNA concentrations were made using the saran wrap over the UV
illuminator technique described above. To visulaize cDNA concentrations, 1 pL of
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ethidium bromide (2 pg/mL) was mixed with 1 pL of the pooled samples and
photographed. cDNA concentrations were estimated by comparing the fluorescent
intensity of the known marker concentrations to the intensity of that of the samples.
Revival of Stock Bacterial Cells from Library Construction Kit (Stratagene)
Splinters were scraped off from a frozen XL-1 Blue MRF' Escherichia coli
glycerol stock with a wire loop and the bacteria placed into small vials. The splinters
were suspended in a drop of sterile water and streaked onto an Luria's Broth (LB) agar
plate. Plates were incubated at 37 C overnight. Following incubation plates were stored
at 4 C and cells were subcultured (restreaked) periodically until used as host cells for
cDNA phage library infection.
Ligating cDNA into the Uni-ZAP XR Vector
A control ligation was set up to ligate the test insert, pBR322, into the Uni-ZAP
XR vector as follows. The components listed below were added in the order listed:
Uni-ZAP XR vector (1 pg) 1 L
Test insert (0.4pg) 1.6pL
1Ox Ligase Buffer 0.5pL
10mM rATP (pH 7.5) 0.5pL
Water 0.9 L
T4 DNA Ligase (4U/pL) 0.5pL (added at the end)
For the cDNA sample the following components were mixed:
Resuspended cDNA 2.5pL
lOx Ligase Buffer 0.5pL
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10mM rATP (pH 7.5) 0.5pl
Uni-ZAP XR vector (1p g/pl) 1.0pL
Water 0.5 L
T4 DNA Ligase (4U/ L) 1.0 L
All samples were incubated at 12*C overnight. In the interim, host bacteria were
prepared by inoculating 6 mL of sterile NZY medium with a single isolated colony taken
from XL-1 Blue Bacteria colonies streaked out and grown on LB agar the night prior to
the start of the protocol. Cultures were grown at 30 C overnight with shaking.
Packaging ligated cDNA into Bacteriophage Extracts
Two packaging extracts were performed per sample, but one sample was
processed at a time. The packaging extracts were quickly thawed and immediately 2.5
pL of ligated DNA was added. Samples were named A/1, A/2, B/1, and B/2 to
correspond to the two original RNA samples A and B and the number of packaging
extracts, #1 and 2. With a pipette tip the mixture was stirred by gently pipetting up and
down ensuring no bubbles formed. The tube was centrifuged quickly to settle contents
and incubated for exactly 110 minutes at 22*C. The packaging process was stopped by
the addition of 500 pL of SM buffer, followed by 20 L of chloroform. The tube was
gently mixed and centrifuged briefly before samples were ready to be titrated. Samples
were stored at 4*C when not in use
Plating and Determination of Titre
The bacterial cells were cultured in NZY medium according to ZAP-cDNA
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Synthesis Kit (Stratagene) and centrifuged at 500x g for 10 minutes at room temperature.
In the interim NZY top agar was liquified and maintained at a temperature between 40-
50 C. Following centrifugation the supernatant was discarded and cell pellet
resuspended, in half the original volume of 10 mM MgSO 4. Cells were adjusted to a
density equivalent of an O.D.600 of 0.5 by diluting with 10 mM of MgSO 4. To 200 L of
bacterial suspension (reading of 0.5 at O.D. 600) 1pL of cDNA library suspension from a
total volume of 500 pL from samples A/i, A/2, B/i, and B/2 was added, mixed and
incubated for 15 minutes at 37 C. Following incubation 3mL of NZY top agar was
added and quickly mixed with the phage and bacteria mixture in a 15 mL polypropylene
tube. The tube was rolled between hands to throughly mix contents which were then
added directly to the middle of an NZY agar plate which in the interim was warmed to
37*C and kept in a styrofoam box to ensure that the NZY top agar did not solify before
completely spreading across the plate. The inoculum was spread quickly over the surface
of the plate with a sterile glass spreader, and any bubbles were removed using a sterile
needle. Plates were allowed to set for 10 mintues and then incubated overnight at 37*C.
The next day the number of plaques per sample were counted and the titre of the cDNA
library was determined in plaque forming units (pfu) employing the following equation:
[number of plaques (pfu) x dilution factor/volume plated (pL)]
The dilution factor was 500 and the volume plated was 1 pL. The size of a good
representational primary library consists of 1 x 106 plaque forming units.
Amplification of the Uni-ZAP XR Library
Bacterial host strains were prepared as described previously. Cells were diluted
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to an O.D.600 of 0.5 in a total volume of 10 mL to be used for each 150mm plate. cDNA
library sample B/2 with a volume of 500 pL was chosen for amplification as its pfu titre
was 1.15 x 106, and since a cDNA library titre of 1 x 106 pfu is considered optimal.
Twenty-two aliquots of 600 pL of the bacterial culture standardized to an O.D. 600 of 0.5
were set up. To each 600 pL aliquot of bacterial cells 1 pL of cDNA library sample was
mixed. Tubes containing this mixture of phage and host cells were incubated at 37 C for
15 minutes. NZY top agar (6.5 pL) was liquified and cooled to 48*C and mixed with the
phage and host cells and quickly spread evenly onto the surface of 150 mm diameter
NZY agar plates as described previously. After the NZY top agar solidified the plates
were incubated at 37 C for 6-8 hours. Plaques were not allowed to grow larger than 1-2
mm in diameter.
Lifting Plaques
Using flat forceps a nitrocellulose membrane was placed onto the surface of each
NZY agar plate (22 plates total) containing the amplified library. The membranes were
left on the agar surface for 2 minutes to allow the transfer of the phage particles to the
membrane. In order to later identify the positive plaques on membranes and agar the
orientation of the membranes was done by making reference points on each membrane as
follows. Using a sterile needle three assymetrical pricks were made through the
membrane, just touching the surface of the top agar. The membranes were peeled off
using the flat forceps and placed plaque-side up onto 3 MM paper or paper towels. The
original plates were stored at 4 C. The membranes were air dried for 30 minutes during
which time the following solutions (500 mL of each) were prepared:
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(i) Denaturing Solution (0.1 N NaOH-1.5 M NaCl)
5 M NaOH 10 mL
5 M NaCl 150 mL
Sterile Water 340 mL
(ii) Neutralizing Solution [0.2 M Tris-HCl (pH 7.4) - 2xSSC
2 M Tris-HCl 50 mL
Sterile Water 400 mL
(iii) 2xSSC
20xSSC 50 mL
Sterile Water 450 mL
The three solutions were added to three separate plastic containers with lids. The dried
membranes were added one at a time to the denaturing solutions so each first floated on
top of the solution's surface and then gently immersed into the solution for 20-30
seconds. The membranes were briefly blotted on a 3MM paper or a paper towel and
submerged into the neutralizing solution for 5 mminutes. The membranes were again
briefly blotted on a 3 MM paper towel and rinsed for 5 minutes in 2xSSC. The
membranes were placed plaque-side up on paper towels and allowed to dry for 30
minutes. The DNA was crosslinked using a UV'Crosslinger at 700,000 pJ-cm2 for the
Hybond-N membranes used.
Preparation of DIG-labeled C3 Probe
The C3 cDNA probe C3A4 (figure 3) used for hybridization was non-
radioactively labeled by incorporation of a digoxigenin-labeled nucleotide. Digoxigenin
is a steroid hapten linked via a spacer arm to the corresponding nucleotide. The DNA
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probe was generated using Klenow polymerase that randomly primed incorporation of
DIG-labeled deoxyuridine triphosphate. Oligonucleotides were enzymatically labeled at
their 3'-end with terminal transferase either by incorporation of a single DIG-labeled
dideoxyuridine-triphosphate. Preparation of a DIG-labeled C3 probe was carried out
using previously isolated and sequenced cDNA plasmid C3A4 (figure 3). The reaction
mixture contained the following:
lOx PCR buffer 5pl
PCR DIG mix 5pl
M13F primer (10 M) 2.5 l
M13R primer (10M) 2.5pl
template plasmid (1 ng/pd) 2l
Sterile Water 33pl
Enzyme mix 0.75pl
All contents were mixed thoroughly and placed in a thermocycler. The thermocycling
parameters optimal for making the C3 probe were:
95*C, 2 minutes
95*C, 10 seconds
50*C, 10 seconds x 30
72 C, 1 minute
4*C, o
When amplification was complete the probe was analyzed by agarose gel electrophoresis
to confirm that the probe was labeled accurately.
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DIG Nucleic Acid Hybridization and Detection Kit
The following solutions were prepared prior to DIG Nucleic Acid Hybridization:
Prehybridization solution
20x SSC 150 mL
10% Blocking Reagent 60 mL
Sterile Water 390 mL
N-lauroylsarcosine (powder) 0.6 g
SDS (powder) 0.12g
500 mL of the prehybridization solution was preheated at 65 C. Residual 100mL was
reserved and used for dilution of the DIG-labeled C3A4 probe. For the secondary
screening this 100 mL was not needed because the diluted probe solution was recovered
and used after the primary screening and stored at 20 C. The plaque-lift membranes
were added into the prehybridization solution and incubated at 65*C for 2 hours in a
hybridization bag for the primary screening.
The DIG labeled C3A4 probe was heated at 95 C for 10 minutes, chilled quickly
on ice, diluted 1/1000 in fresh prehybridization solution. After 2 hours, the
prehybridization solution was removed from the membranes and membranes were
sumberged completely in probe solution (prehybridization buffer with DIG labeled
C3A4 probe) inside hybridization bags. Before sealing the hybridization bags all air
bubbles were removed. Membranes were hybridized with the probe at 65*C overnight
(16 hours). During the overnight incubation the following washing solutions were
prepared:
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2x Wash solution (2x SSC- 0.1% SDS)
20x SSC 100 ml
Water 900 ml
SDS powder ig
0.1x Wash Solution (0.1xSSC- 0.1% SDS)
20x SSC 5 ml
Water 995 ml
SDS Powder ig
The next morning, the membranes are removed and washed twice in 500 mL of preheated
(65*C) 2x Wash Solution and incubated in 2x Wash Solution for 5 minutes at room
temperature (25 C) with shaking. The probe solution was recovered from the bags and
stored at -20*C. After 5 minutes, the membranes were placed into 500ml of 0.1 x Wash
Solution (heated to 65*C) for 30 minutes. The membranes were washed after 30 minutes
in 500 mL of DIG buffer-2 (0.1 M Maleic Acid-NaOH Buffer, 0.15 M NaCl, pH 7.5) at
room temperatrure (25 C) for 5 minutes with shaking, then incubated in 300 ml of DIG
Buffer-2 (1% Blocking reagent in DIG buffer-1) at room temperature for 30-60 minutes.
After this incubation, they were placed in 200 ml of DIG buffer-2 containing 4 0 pl of
anti-DIG-alkaline phosphatase at room temperarture for 30 minutes. After washing the
membranes three times with 500 ml DIG buffer-1 at room temperature for 15 minutes
with shaking, they were incubated in 200 ml of DIG buffer-3 (0.1M Tris-HCl, pH 9.5, 0.1
M NaCl, 0.05 M MgCl2) at room temperature for 5 minutes. The DIG Buffer-3 solution
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was prepared by mixing:
1 M Tris-HCl (pH 9.5) 20 ml
5 M NaCl 4 ml
Sterile Water 166 ml
1 M MgCl2 (autoclaved) 10 ml
The membranes were incubated in 200 ml of NBT/BICP substrate solution until positive
plaques developed a blue-purple color. The color development was stopped by
immersing the membranes in TE buffer (10 mM Tris-HCl, 1mM EDTA, pH 8.0). After
30 minutes, the membranes were dried on paper towels and stored in TE buffer at 4*C.
Positive Plaque Collection
Membranes were placed on top of a transparency sheet and covered with another
transparency sheet with the plaque-side of the membrane uppermost it was traced onto
the top transparency. The position of the needle marks were marked on to the
transparencies and the positive plaque positions traced. The labeled transparency sheet
was placed traced side up on a bench and its corresponding NZY agar plate containing
the plaques was placed on the labeled sheet and adjusted to correspond to the needle
marks taken from the membranes to those made on the agarose plate. The plates were
oriented according to the traced needle marks of the transparency that corresponded to
the original needle marks made on the top agar.
A 2 mL pipetman tip was cut at the point where a 4mm diameter can be formed.
Using the tip, positive plaques were removed by inserting the tip into the top and bottom
agar. Suction was used to draw out the agarose plug. The agarose plug containing the
plaque was added into 500 pl of SM buffer containing 20 pl of chloroform. Samples
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were vortexed 20 seconds and incubate overnight at 4 C to extract phage particles. This
phage stock is stable at 4*C for 6 months. The phage isolated from this 1st screening was
used for the secondary screening.
Secondary Screening
A second screening was performed to obtain phage containing only the cDNA
that gave a positive result in the first screening. Dilutions of the resuspended plaque were
made. The primary phage stock isolated from the agarose plugs after primary screening
were diluted 1/1000, 1/5000, and 1/10,000 using SM Buffer. From these dilutions lpi of
the phage stock was added to 200 pl of bacterial cell suspension equivalent to an O.D.600
of 0.5. The cell mixture was incubated and plated as described above for the primary
screening, the only difference was that for this secondary screening 1 00x15 mm plates
were used and only 3ml of NZY top agar was needed. Plates were incubated overnight.
Hybridization and detection was performed as above. Identified positive plaques were
isolated by cutting out the agarose plug containing the plaques as described previously.
A total of 50 plaques gave positive hybridization results to probe C3A4 and they were all
isolated.
InVivo Excision Protocols Using ExAssist Helper Phage with SOLR Strain
The ExAssist helper phage and SOLR bacterial strain allows efficient excision of
the pBluescript phagemid from the Uni-ZAP XR vector. The helper phage contains an
amber mutation that prevents replication of the phage genome using the SOLR cells as
the host strain. Only the excised phagemid will replicate in the host so that risk of
coinfection with the helper phage does not occur. In order to excise the pBluescript
phagemid from the Uni-ZAP XR vector the following protocol was followed. The 50
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resuspended plaques were vortexed to release the phage particles and incubated for 1-2
hours at room temperature (25 *C). Separate cultures of XL 1-Blue MRF' and SOLR cells
were grown in LB broth overnight at 30 C. The overnight cultured XL 1-Blue MRF' and
SOLR cells (1000xg) were centrifuged for 10 minutes and pellets resuspended to an
O.D.600 of 1.0 in 10 mM MgSO4. For in vivo excision of the vector the following
components were mixed in 15 mL polypropylene tube:
XL1-Blue MRF' cells at an OD600 of 1.0 200pl
Phage stock (containing >1 x 10 6 pfu/pl) 2 50 1
ExAssist helper phage (>1 x 10 6 pfu/pl) 1 l
The sample mixtures were stirred gently and incubated at 37 C for 15 minutes. After
incubation 3mL of LB broth was added and incubated 2.5-3 hours at 37*C with shaking.
The sample was then be heated at 65-70 C for 20 minutes and centrifuged at 1000xg for
15 minutes. The supernatant was decanted into a sterile 15 mL tube and saved. This
supernatant contained the excised pBluescript phagemid containing the cDNAs of interest
and packed as filamentous phage particles.
Excised phagemids were plated by adding 200 pl of freshly grown SOLR cells at
an O.D. 600 of 1.0 to two 1.5ml microcentrifuge tubes. Two different volumes of excised
phagemid were used to transform bacterial cells and obtain cloned cDNA into a
pBluescript vector. 100 pl of each phage supernatant was added to one set of
microcentrifuge tubes and 10pi of the phage supernatant was added to the other set of
tubes. The tubes were incubated at 37*C for 15 minutes. 200pl of the cell mixture was
plated from each tube onto LB ampicillin plates (50pg/ml) and incubated overnight at
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37*C. The next day, single colonies were visible on all plates and one colony from each
plate was isolated with a toothpick and streaked onto LB ampicillin plates and inoculated
into LB Ampicillin broth to isolate the plasmids using Promega's SV Wizard MiniPrep
Kit. Cycle PCR sequencing using Big Dye Terminators and M13 primers forward and
reverse (Table 1) was performed on all 50 clones.
Primer Name (sense or Primer Sequence
antisense) 5' to 3'
M13 Reverse (sense) ggaaacagctatgaccatg
M13 Forward (antisense) gtaaaacgacggccagt
Thiolester Primer aggaattcggntgyggngarcaracnatg
Primer I/S (sense) cctgataaagggaccagcaa
Primer I/AS (antisense) tggcactgaacttctgttgg
Table 1. Primers used for obtaining nucleotide sequence of the C3 clones isolated from
the cDNA library. M13 Reverse and Forward primers flanked the cloned insert at the 5'
and 3' end. The thiolester primer was used to obtain sequence in that region. Primer I/S
and Primer I/AS were designed using Primer 3 program to obtain internal sequence of the
cloned C3 inserts.
Restriction Enzyme Digestion of C3 Confirmed Plasmids
Insert sizes were determined by digesting samples with two restriction enzymes
that flanked the cDNA inserts on the vector. The two enzymes used were EcoRI and
Hind I. Electrophoretic analysis on a 1x TBE, 1% Agarose gel of the digested plasmids
along with a low DNA mass ladder was performed to visualize the digested clones. This
confirmation allowed us to proceed with obtaining additional sequence data by
demonstrating that our C3-like clones were longer than the approximate 1000 bp of
nucleic acid sequence obtained.
Design of Internal Primers
For all sequencing materials (16A1.2/1, 16A1.2/2, 16A1.3/2, and 20A1.3/2), M13
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Forward and Reverse primers were used since the primer templates flanked our C3
cDNA cloned inserts. After obtaining nucleotide sequence data, we decided to use only
one of the samples from the 16A group, that is, 16A1.2/1. From this sequence two
primers were made of which there was a sense primer (Primer I/S) and an antisense
primer (Primer I/AS) using Primer3 Program (available at http://www-
genome.wi.mit.edu/cgi-bin/primer/primer3 www.cgi) (table 1). Another primer we used
was one that would recognize the thiolester region and corresponded to the conserved
thiolester sequence CGEQNM (table 1).
Sequence Analysis and Alignments
Samples were sequenced using the ABI 377 DNA Sequencer and analyzed using
the BLAST program from www.ncbi.nlm.nih.gov to identify whether the sequences of
isolated clones aligned with known C3 sequences. Only 4 clones gave positive sequence
alignments with C3 of several organisms. Nucleotide sequences were submitted to the
BLAST program and their reading frame identified. DNA translations were carried out
using GeneDoc software to identify the proteins. Alignments were carried out in the
Clustal X program using its default parameters. Alignments were saved as multiple
sequence format (MSF) for use in GeneDoc where sequences were further aligned and
edited, and their similarity, identity, conservation, and physiochemical property
similarities could be determined.
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IV. Results
Total RNA Isolation from Nurse Shark Liver
Total RNA was isolated from 0.5g of nurse shark liver. The 260nm/280nm ratio
was 1.570 and the concentration was 11.6pg/pl. The integrity of the RNA was analyzed
electrophoretically on a lx TBE agarose gel (figure 4). Each diluted RNA sample
showed two prominent bands representing the 28S and 18S species of ribosomal RNA,
along with a smear ranging from 400bp to 8kb representing a heterogenous family of
mRNA. Each sample displayed an intense fluorescent band at the top of the lane which
suggests the presence of large fragments of DNA which are unable to enter the gel during
electrophoresis due to their large size. Alternatively, this may be due to an initial drop in
pH of the sample caused by the TRIZOL reagent causing excess RNA to remain in the
wells and not migrate across the gel.
Isolation of mRNA
Isolation of mRNA is necessary to provide the template for cDNA synthesis. The
latter represents the genes expressed by the nurse shark liver and forms the cDNA library.
Two separate samples of mRNA were prepared using different amounts of total RNA as
starting material. The concentration of total RNA was 12 pg/pl and The protocol
required approximately 500pg of total RNA. For isolation of mRNA, 40 pl, (sample A)
and 80 pl (sample B), (i.e. 480 pg and 960 pg respectively) was used. Two different
concentrations of RNA were used to ensure that one of the concentrations would be
sufficient for the preparation of cDNA. The two samples were labeled A and B,
representing the 40 L and 80 L, respectively, of total RNA used. The concentration of
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2.37kb *
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0.24 kb
Figure 4. Electrophoretic analysis of total cellular RNA in a 1% agarose, 1 x TBE gel.
RNA isolated from the nurse shark liver was diluted 100, 500, and 1000 fold. The 100,
500, and 1000 dilutions were run in lanes 2, 3, and 4, respectively. The gel was stained
with ethidium bromide. The 18S and 28S ribosomal RNA bands of the RNA ladder run
in lane 1, are indicated by arrows. All three diluted samples contained RNA. The
smearing observed in the lanes represents mRNA in the sample. The additional discrete
molecular weight bands may correspond to small rRNA or tRNA. The high molecular
weight remaining in the well may be a result of high molecular weight RNA or DNA, or
a result of overloading the gel with a high concentration of RNA which can not migrate
through the gel properly.
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the mRNA isolated was not determined spectrophotometrically because the procedure
would have consumed one-third of the sample yield. Thus, the mRNA samples were
used directly for cDNA synthesis without determining RNA concentration.
cDNA Synthesis
First and Second Strand Synthesis
The cDNA synthesis from the mRNA samples was performed using the Zap
cDNA Synthesis Kit from Stratagene. First-strand synthesis was performed on both
mRNA samples, A and B. The protocol required at least 5 pg of mRNA and a total
volume of 37.5 pL mRNA could be used in the reaction mixture. Since quantitation of
mRNA was not performed the total volume of mRNA permitted was used. From mRNA
preparation A, 37.5 pl of sample was taken while 25pl of mRNA sample B was used.
Results of electrophoretic analysis of products of first and second-strand synthesis using
samples A and B are illustrated in figure 5. Lanes, two and three, containing cDNA for
mRNA sample A and sample B, respectively, show a faint smear in cDNA samples. The
faintness of the smear may be due to the small amount (5pl) of cDNA sample taken from
the reaction mix for electrophoretic analysis. The presence of a cDNA smear indicated
that the sample contained the range of cDNA sizes synthesized. The cDNA was
precipitated, washed, and resuspended in 8 L in a mixture containing EcoRI adapters,
ligase, and buffer.
Ligation of EcoRI Adpaters and cDNA Size Fractionation
After ligation of EcoRI adapters to the cDNAs, size fractionation was performed to
separate unligated adapters (small molecular size) from cDNAs ligated with adapters.
For each cDNA preparation (A and B) twenty column fractions were collected, each
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1 2 3
2.0 kb
1.8 kb -+
0.8 kb -
0.4 kb -
0.2 kb -+
0.1kb
Figure 5. Electrophoretic analysis of cDNA synthesized from mRNA. cDNA samples,
corresponding to mRNA preps A and B, were run in lanes 2 and 3 in 1% agarose, lx
TBE gel. Lane 1 contained the low mass DNA ladder (GibcoBRL) and bands
corresponding to 2, 1.8, 1.0, 0.4 kb are indicated by arrows. Faint smearing can be
observed in the sample lanes indicating successful first and second strand synthesis. The
gel was stained with ethidium bromide.
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consisting of 6 drops, approximately 400 L/each drop. To estimate the concentration of
cDNA in a 2 L aliquot from each fraction was mixed and stained with 2 pL of ethidium
bromide and spotted onto saran wrap spread over an ultra violet lamp. For comparison a
low mass DNA ladder with concentration of 117.5 ng/pL was serially diluted (double
dilutions) from an initial 1/5 dilution. Drops of each marker dilution were placed in a
row on the saran wrap and examined for intensity of fluorescence. In figure 6a, the dots
represent marker concentrations (ng/pl) corresponding to: 0, 0.734, 1.46, 2.9375, 5.875,
11.7, 23.5, and 117.5. In the middle panel of figure 6b, the two rows of spots increasing
in fluorescence intensity from left to right are the 20 fractions collected from sample A
drip column. The lower panel of figure 6c illustrates the two rows of spots representing
20 fractions collected from sample B which show increasing fluorescence from left to
right. In the photograph a higher UV intensity corresponds to increasing sizes of the
cDNAs. The fractions with less intensity may have present in them the EcoRI adapters
and residual liner-primer that are much smaller in size than the cDNAs. It was not clear
whether EcoRI adapter or residual linker-primer was in samples with less intensity
because our blank, which contained ethidium bromide in water, demonstrated some UV
fluorescence. For sample A, fraction #6 through fraction #12 showed higher levels of
fluorescence and were pooled after electrophoretic analysis (figures 6 and 7). Similarly
for sample B, fraction #26 through #32 showed higher fluorescence and were pooled.
To reliably confirm and identify the cDNA-containing fractions which could be
pooled together, fractions were analyzed electrophoretically. All fractions were
electrophoresed in lx TAE agarose gel (1%) using 5pL sample of each fraction (figure
7). Faint smears corresponding to cDNA could be observed in several lanes, which
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(a)
(b)
Figure 6. Estimation of cDNA concentration in column fractions. The top panel (a)
shows dilutions of cDNA marker concentration ranging from zero (dot #1) only contains
water) to 117.5 ng/ d (dot #8) (see text for details). An increasing concentration of
cDNA is observed as intensity of fluorescence of the dots (ethidium bromide-stained).
The middle (b) and lower (c) panel dots represent the 20 size fractions obtained for the
two processed cDNA samples, A and B, respectively.
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Figure 6. Estimation of cDNA concentration in column fractions. The top panel (a)
shows dilutions of cDNA marker concentration ranging from zero (dot #1) only contains
water) to 117.5 ng/.d (dot #8) (see text for details). An increasing concentration of
cDNA is observed as intensity of fluorescence of the dots (ethidium bromide-stained).
The middle (b) and lower (c) panel dots represent the 20 size fractions obtained for the
two processed cDNA samples, A and B, respectively.
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Figure 7. Electrophoretic analysis of column fractions for cDNA samples A and B.
cDNA samples A and B were fractionated on a Sepharose CL-2B gel filtration column.
Fractions were electrophoretically analyzed on a 1 x TAE, 1% agarose gel. Fractions # 1
through #20, from sample A were run in lanes #2 through #20, while fractions # 10
through #20, from sample B were run in lanes #22 through #32. Lanes 1 and 21
contained the low DNA mass ladder. Fractions #6 through #12 (lanes 7-13) of sample A
and fractions #14 through #20 (lanes 24-32) of sample B showed presence of cDNA
(faint smearing) and were pooled.
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Figure 7. Electrophoretic analysis of column fractions for cDNA samples A and B.
cDNA samples A and B were fractionated on a Sepharose CL-2B gel filtration column.
Fractions were electrophoretically analyzed on a 1 x TAE, 1% agarose gel. Fractions # 1
through #20, from sample A were run in lanes #2 through #20, while fractions # 10
through #20, from sample B were run in lanes #22 through #32. Lanes 1 and 21
contained the low DNA mass ladder. Fractions #6 through #12 (lanes 7-13) of sample A
and fractions #14 through #20 (lanes 24-32) of sample B showed presence of cDNA
(faint smearing) and were pooled.
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identified which fractions to pool together. Fractions #6 through #12 (lanes 7-13) of
sample A were selected, and fractions #14 through #20 (lanes 24-32) from sample B were
selected to be pooled. Fractions not selected were discarded. Another saran wrap spot
test was performed after the appropriate fractions were pooled for each sample (figure 8).
Four different concentrations of the low DNA mass ladder (GibcoBRL) were spotted
corresponding to: 13ng/pl, 25ng/ l, 49ng/ l and 98ng/ l. A 1 pL aliquot of pooled
fractions of sample A and sample B were also spotted. Visual analysis estimated the
concentration of cDNA in each sample to be approximately 50ng/pl for both samples A
and B. cDNA inserts of sample A and sample B and the test insert were all ligated into
the Uni-Zap XR Vector.
Packaging Uni-ZAP XR Library into Extracts, Plating and Titration
Packaging of cDNA Library into Extracts
The cDNA Uni-ZAP XR library was packaged into lambda phage extracts. Two
extracts were used per sample (sample A/1, A/2, B/1 and B/2). After samples were
packaged the initial phage titration was carried out on small size plates initially to
determine the efficiency and plaque forming units (pfu). The total volume of each library
constructed was 500pl. One microliter of each sample was used for the titration. The
total titre in plaque forming units (PFU) was calculated using the following equation:
[number of plaques (pfu) x dilution factor/volume plated (1 pL)]
After incubation of the phage sample with host bacteria, the plaques on each plate were
counted (Table 2) and the pfu titre for each library sample determined. The optimal pfu
for a cDNA library is considered to be 1 x 106. Results from all four samples indicated
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Figure 8. Estimation of cDNA concentration in pooled fractions of samples A and B.
Dotsl-4 represent the four dilutions of the low mass DNA ladder (GibcoBRL): 13ng/pl
(dot 1), 25ng/ p (dot 2), 49ng/gl (dot 3), and 98 ng/pl (dot 4). Dot 5 and 6 represent the
pooled fractions for sample A and B, respectively.
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cDNA Library No. of Plaques Plaque Forming Units
A 3568 1.78 x 10
A/1 2364 1.18 x 10
B 2872 1.43 x 10
B/1 2304 1.15 x 10
Table 2. Determination of plaque forming units of library samples. The number of
plaques on each 100 x 15mm plate were counted and the number of plaque forming units
of each cDNA library was calculated using the following equation:
(number of plaques) x dilution,
volume plated
(volume equals 1 pl and the packaging volume was 500 l.)
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good efficiency. Of the four samples, sample B/2, which contained a titre of 1.15 x 106
pfu was selected for further amplification and screening.
Amplification of Library and Screening of cDNA Library
Amplification of cDNA library sample B/2 was achieved following the protocol
outlined in Materials and Methods. Twenty-two plates were prepared with NZY agar and
layered with soft top NZY agar containing bacteria that had been incubated with 23 1 of
cDNA library extracts. After 8 hours of incubation a bacterial lawn was present with
plaques spread throughout all the plates. All plates were suitable for performing plaque
lifts that were then screened with the Digoxigenin labeled C3A4 probe.
Preparation of DIG Labeled Probes
Probes for screening cDNA library were labeled with non-radioactive digoxigenin
using the DIG-PCR Kit (Amersham Pharmacia). Electrophoretic analysis of labelled and
unlabelled probe is shown in figure 9 which illustrates profile of nonlabeled C3A4 (lane
1) and labeled C3A4 (lane 3) probe. Molecuar size determinations were made by
comparison with bands of a Low DNA Mass Ladder. The sizes of the unlabelled probe
samples had an insert size of 220bp while labeled probe samples banded at approximately
400 bp because of the added size of label, digoxigenin.
Plaque Lifts
Plaque lifts were performed on all 22 plates. The plates were labeled P 1-22. Two
hybond N membranes (Amersham) were used per plate. Each membrane was labeled
according to plate number and probe that would be used to screen for C3. The probe
used were C3A4 and C3A7. However, because of the complexity of the project, only
results from screening with probe C3A4 will be reported. The letter A identifies the
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4- 400 bp
- 200 bp
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Figure 9. Agarose electrophoresis of DIG-labeled probes. La+nes 1 and 2 contain the
440bp DIG-labeled C3A4 PCR product. Lanes 3 and 4 contains the 440bp DIG-labeled
C3A7 PCR product. Non-labeled PCR products for C3A4 and C3A7 can be seen in lanes
5 and 6, respectively, and have a molecular weight of 220. PCR products of the control
template containing C3A4 is in lane 7. Low DNA Mass Ladder was run in lane 8, and
size indicated by arrows..
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Figure 9. Agarose electrophoresis of DIG-labeled probes. La+nes 1 and 2 contain the
440bp DIG-labeled C3A4 PCR product. Lanes 3 and 4 contains the 440bp DIG-labeled
C3A7 PCR product. Non-labeled PCR products for C3A4 and C3A7 can be seen in lanes
5 and 6, respectively, and have a molecular weight of 220. PCR products of the control
template containing C3A4 is in lane 7. Low DNA Mass Ladder was run in lane 8, and
size indicated by arrows..
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plaque lifts that were screened with C3A4. Letter A corresponded to probe C3A4. For
example, 1A denoted plaque lift collected from plate 1 and screened with probe A4,
whereas, 1B denotes plaque lifts from plate 1 screened with C3A7 (not reported).
Because of the complexity of the project, only results from screening with probe C3A4
will be reported.
Screening of Plaque Lifts
The primary screening of all plaque lifts was performed with the digoxigenin
labeled C3A4 probe. Positive reactions were identified by the color reaction created by
detection of the DIG labeled probe that hybridized to plaques containing potential C3
inserts. The color reaction created a bluish purple dot. There were many positive
reactions, of which it was not possible to determine if they were all false positives;
therefore, sixty samples were randomly selected from all the plates and collected.
Collection of samples required isolation and removal of the agarose plug
containing the plaque that gave the positive reaction with probe. Since the distances
between plaques were so small a secondary screening had to be done to isolate single
phage plaques that had no contamination from neighboring plaques. Labeling of the
plaques collected (as listed in table 3) was as follows: plate number, probe used for
screening, and plaque number, that is, P4A2.2/1 corresponds to Plate #4, screened with
C3A4 probe, yielding plaque #2.2/1.
Secondary Screening
Secondary screening was performed only on samples isolated using the A4 probe.
The collected agarose plugs were vortexed in SM buffer and chloroform, and the phage
particles released. A small amount of the phage sample was mixed with host bacteria,
54
Isolated and Isolated and
Sequenced Identified as C3 Sequenced Identified as C3
Pha emids Phagemids
P2A1.3/1 - P4A2.3/2 -
P2A1.3/2 - P5A2.1/1 -
P2A1.3/3 - P5A2.1/2 -
P2A1.3/4 - P7A2.2/1 -
P2A1.4/1 - P7A2.2/2 -
P2A1.4/2 - P7A7.2/1 -
P2A2.1/1 - P7A7.2/2 -
P2A2.1/2 - P7A7.3/1 -
P2A2.1/3 - P7A7.3/2 -
P2A3.1/1 - P9A2.2/1 -
P2A3.1/2 - P9A2.2/2 -
P2A6.1/1 - P1OA2.1/2 -
P2A6.1/2 - P16A1.2/1 +
P2A6.1/3 - P16A1.2/2 +
P2A6.1/4 - P16A1.3/1 -
P2A6.2/1 - P16A1.3/2 +
P2A6.2/2 - P16A1.4/1 -
P3A8.1/2 - P20A1.1/1 -
P4A1.3/1 - P20A1.1/2 -
P4A1.3/2 - P20A1.2/1 -
P4A2.1/1 - P20A1.2/2 .
P4A2.1/2 - P20A1.3/1 -
P4A2.2/1 - P20A1.3/2 +
P4A2.2/2 - P20A2.1/1 -
P4A2.3/1 - P20A2.1/2 .
Table 3. Identification of C3-like clones isolated from the library. Of the 48 samples
excised only 50 gave phagemids that were isolated and then sequenced. After performing
BLAST searches on NCBI only samples were identified as C3-like sequences:
P16A1.2/1, P16A1.2/2, P16A1.3/2, and P20A1.3/2
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plated on 11 Ox 15 mm size NZY agar plates, and incubated for secondary screening.
After overnight incubation, plaque lifts were prepared using smaller Hybond-N
membranes and then screened with the A4 DIG-labeled probe. The secondary screening
led to the isolation of 58 plaques containing potential C3 cDNA inserts (Table 3). The
labeling of these isolates consisted of adding the plaque number from the secondary
screening.
In Vivo Excision of the pBluescript Phagemid from the Uni-ZAP XR Vector
The Uni-ZAP XR Vector allowed in vivo excision and recirculization of any
cloned insert contained within the lambda vector to form phagemids containing the
cloned insert. All 58 samples that gave positive signals after screening with hybridized
Digoxigenin C3A4 probe was subject to excision and conversion to phagemids. All
isolates formed several bacterial colonies containing the phagemids. Fifty (50) random
colonies were isolated with a sterile toothpick onto a master plate containing LB agar and
ampicillin (50pg/mL) and the toothpick containing the isolated colony was dipped into
3mL of LB and ampicillin broth from each sample and grown overnight at 37*C. The
"phagemid" DNA was isolated from each bacterial culture using the methods described
previously for DNA isolation using the Qiagen SV Miniprep Kit. The 50 DNA samples
isolated were labeled as described except that a fourth number describing the colony
number picked was added to the end of the series (Table 3) describing the cloned isolate.
Sequencing Reactions
All 50 phagemid samples purified were subject to cycle sequencing PCR using
M13 forward and reverse primers (Table 1). A control sample was also prepared using
the standard pGEM control that was supplied with the Big Dye Sequencing Kit. After
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PCR and labeling of the samples for sequencing all samples were ethanol precipitated
and washed. Samples were sequenced using ABI 377 Sequencer.
Samples were sequenced on 48 cm plates that provided us with sequences of more
than 800 base pairs. Data was analyzed initially using the NCBI Blast database in which
the DNA sequences are automatically converted into protein and then checked against all
the amino acid sequences in the database. Of the 50 samples sequenced, four samples
displayed similarity to C3 in other organisms, the samples were: 16A1.2/1, 16A1.2/2,
16A1.3/2, and 20A1.3/2 (Table 3). Sequence data from the sense and anti-sense direction
was obtained (figure 10 and figure 11). After initial confirmation that these four samples
were in fact shark C3-like clones sequence alignments using Clustal X (figure 11) and
Genedoc computer programs were performed to determine similarity and identity
between clones (figure 10 and figure 11). Clones P16A1.2/1, P16A1.2/2, and P16A1.3/2
had approximately 90% identity with each other and approximately 44% identity with
clone 20A1.3/2 (figure 10 and 11). Furthermore, the size of the inserts (i.e. clones) was
determined by electrophorectic analysis (figure 12).
Size Determination of Inserts
Insert sizes were determined by digesting samples with two restriction enzymes
for which cleavage sites flanked the cDNA inserts on the vector (figure 12). The two
enzymes used were EcoRI and Hind III. Electrophoretic analysis on a lx TBE, 1%
agarose gel of the digested plasmids along with a low DNA mass ladder displayed the
fragment pattern for each sample (figure 12). Clones, P16A1.2/1 (Clone I), P16A1.2/2
(Clone II), and P16A1.3/2 (Clone III) had identical banding patterns when cut with
EcoR] and HindIIl, whereas P20A1.3/2 (Clone IV) had a different banding pattern and
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Clone I Clone III
E H
4.36 kb -
2.3 kb
2.0 kb
Clone IV Clone II
Figure 12. Electrophoretic analysis of restriction digests of Clones I, II, III, and IV.
Clones I, II, III, and IV (16A1.2/1, 16A1.2/2, 16A1.3/2, and 20A1.3/2, respectively) were
digested with restriction enzymes EcoRl (E) and HindIII (H). A k DNA/HindIII
fragment ladder was run on lane 1 and arrows indicate band size. Digests of Clones I, II,
III, and IV were run in lanes 2 and 8, and 7 and 10, 9 and 11, and 3 and 4, respectively.
Clones I, II, and III gave similar size restriction fragments (4.0 kb and 2.5 kb, with E, and
4.3 kb and 2.2 kb, with H), while restriction fragment pattern of Clone IV was different
(4.2 kb and 3.3 kb, with E, and 5.3 kb and 2.2 kb, with H).
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was larger in the total size of the insert (figure 12). Digestion with EcoRl produced two
bands for the three P16A clones isolated from P16, while two bands at approximately 4.2
kb and 3.3 kb, were obtained for sample P20A1.3/2. Digestion with HindII produced
two fragments banding at 4.3 kb and 2.2 kb for the P16A clones (I, II, III) and for clone
P20A1.3/2 (IV) bands formed at 5.3 kb and 2.2 kb. The size of the pBluescript insert is
2.9 kb. The estimated size of our 16A plasmids appears to be 6.5 kb meaning that our
insert sizes are approximately 3.5 kb. The P20A1.3/2 clone plus plasmid was 7.5 kb in
size and therefore its insert is estimated to be 4.5 kb. The human C3 cDNA is 5 kb in
length and at present we are unable to estimate the size of the complete nurse shark C3
cDNA, however, our results suggest it to be larger than 3.5 kb.
Analysis of C3-Like Clones
The C3-like clones P16A1.2/1, P16A1.2/2, and P16A1.3/2 were considered to be
identical and therefore, clone P16A 1.2/1 (Clone I) was chosen as the representative of all
three for further sequence analysis. Additional sequence data was obtained by designing
gene specific primers, Primer I/S and Primer I/AS, that would provide us with additional
sequence data for 5' and 3' ends of the inserts (Table 1). The thiolester primer sequence
(CGEQNM) was used to obtain sequence data downstream of the thiolester region. A
total of 2262 nucleotides were sequenced and the deduced amino acid sequence
determined for for 754 residues. Edited results of Clone I (P16A 1.2/1) using primers
M13 Reverse, Primer I/S, Thiolester Primer, M13 Forward, and Primer I/AS are
illustrated in figures 13, 14, 15, 16 and 17, respectively, in which primer regions and
biologically significant sites are denoted by boldface. The deduced amino acid sequences
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tec ccc ggg ctg cag gaa ttc ggc acg agg cct cgt gcc cga att cgg cac gag ggt ggt tcg gta
S P G L Q E F G T R P R A R I R H E G G S V
aac tac ttg cac att ggt att caa ccg gca gaa eta aat cct gga agt aat tta gta gtt cat etc agt
N Y L H I G I Q P A E L N P G S N L V V H L S
etc cgt aat gac aat gca gat gte cag aac cag ata aag tat ttc age tac atg ttg ata aac aaa gga
L R N D N A D V Q N Q I K Y F S Y M L I N K G
aag att gtg gta gtt gga cga cag ega agg gaa att gge caa att gtg gtg aac atg etc att cca ate
K IV V V G R Q R R E I G QI V V NM L I P I
Primer 11S
act tet gac tta ata cca tec ttc aga ctg ctg gte tat tac tac ctg ata aag gga cca gca ata gaa
T S D L I P S F R L L V Y Y Y L I K G P A I E
atg gtt get gat tet gta tgg gtt gat gtg aaa gac aca tgc atg gga aaa ttg ata gtg tet get gca
MV AD SV WVDVKD TCM GKL I VSAA
aac gaa cac gat gaa aat aag ate tac aaa cct gge aaa cag ttt caa ctg aaa ate acg ggt gac
NE HD ENK I YKP GKQF QLKI T G D
Figure 13. Nucleotide and deduced amino acid sequence of C3 clone P16A1.2/1
(Clone I) using M13 Reverse Primer.
68
Primer I/S
act tct gac tta ata cca tcc ttc aga ctg ctg gte tat tac tac ctg ata aag gga cca gca ata gaa
T SD L I P S F R L L V Y Y Y L I K G P A I E
atg gtt get gat tct gta tgg gtt gat gtg aaa gac aca tge atg gga aaa ttg ata gtg tct get gca
MV AD S V W V D V K D T C M G K L I V S A A
aac gaa cac gat gaa aat aag ate tac aaa cet gge aaa cag ttt caa etg aaa atc acg ggt gae
N E H D E N K I Y K P G K Q F Q L K I T G D
tet ggg gca aca gtt ggt etc gtt get gtg gat aaa get gtg tte gtg ttg aat aag aaa aat aaa tta
S G A T V G L V A V D K A V F V L N K K N K L
acg cag age aag ate tgg gac att gtg gag aag aat gac ate gge tgt acg get gga agt gge agt
T Q S K I W D I V E K N D I G C T A G S G S
gat gtt ett ggt gtt tte aca gat gca gga eta aca att gta aca age agt aac etc aag acg get aca
D V L G V F T D A G L T I V T S S N L K T A T
Q/ a cut site
aga aca gac etg acg tge aag cag cca atg aaa egt aga egt egt gca acg aga ett atg gat gtt
R T D L T C K Q P M K R R R R A T R L M D V
aag atg get aaa ttg aat cag tac aag gcg aaa ata tta aat aaa tge tge aac gat gga atg aaa
KM A K L N Q Y K A K I L N K C C N D G M K
ega aac ccc atg ggg ttt tea tgt gca ege aga gca agg aga ata aca caa cgg gaa gac tgt aaa
R N P M G F S C A R R A R R I T Q R E D C K
get gcc tte ctg gae tgt tgc aac cac gte caa aaa ttt aag
A A F L D C C N H V Q K F K
Figure 14. Nucleotide and deduced amino acid sequences of C3 clone P16A1.2/1
(Clone I) using an internal gene specific sense primer (Primer US).
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Thiolester Primer
(CGEQNM)
TTG GCT TAT CGN CAA CCC CNT GGT GCT TAT GCA GCA
L A Y R Q P X G A Y A A
TTT CTA AAT CGA GAA CCG AGC ACG TGG TTG ACT GCT TAT GTG GTG
F L N R E P S T W L T A Y V V
AAA GTA TTC GCA ATG TCA TTC AAT TTG ATC GTA ATT GAT CCA AAT
K V F A M S F N L I V I D P N
GTT CTA TGT GGA GCT GCA CAG TGG CTG ACA TTA AAT AAA CAG AAG
V L C G A A Q W L T L N K Q K
CCT GAT GGT TCA TTC AAA GAA GAT GCT CCC GTA ATT CAT GGA GAG
P D G S F K E D A P V I H G E
ATG ATT GGA GGA GTC AAG GGA TCG GAA AGT GAT GCT TCA CTG ACT
M I G G V K G S E S D A S L T
GCA TTT GTA CTC ATT GCA TTG GTT GAG TCT AAG GCT GTT TGC TCT
A F V L I A L V E S K A V C S
CCT TAC ATA GAG AGT TAT GAA GAC AGC ATC CAA AAA GCA GGA
P Y I E S Y E D S I Q K A G
CAA TAC CTG AAC AAT CGA TTT AAT AAT CTG AAG AGA ACA TAC CCT
Q Y L N N R F N N L K R T Y P
GTG ACA ATA ACA GCC TAT GCA CTT TCA TTA GTG AAC ATC AAC AAA
V T I T A Y A L S L V N I N K
CTG GAC ACC CTG ATG ATG TTT GCT TCA GAA GAC CAA ACA TAC TGG
L D T L M M F A S E D Q T Y W
GCA GAT GCT GGC
A D A G
Figure 15. Nucleotide and deduced amino acid sequence obtained for clone C3 clone
P16A1.2/1 (Clone I) using the internal sense thiolester primer (CGEQNM).
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TTT AAT GTG GAC TCG GAC AAT GAT TAT CTA CTG ATG GGG CAG
F N V D S D N D Y L L M G Q
GGA TCA GAC TTG TGG AGT GAT GGT AAA AGG ATC AAC TAT CTG
G S D L W S D G K R L N Y L
Primer I/AS
ATT GGA GAT GGA ACC TGG TTG GAA TTT TGG CCA ACA GAA GTT
I G D G T W L E F W P T E V
CAG TGC CAA AAT CAA AAA TAC CGC AGA CTC TGT CAG AGC CTA
Q C Q N Q K Y R R L C Q S L
GCA GAG TTT TCT GAA AGC TTA ATG ATT AAT GGC TGC CCG ACT
A E F S E S L M I N G C P T
Stop
Codon 3'Untranslated Region 1'
TAA TAT TTT TGT TTC ATA AAT AAT CAG TGT TAT TTA CAT CCA
- Y F C F I N N Q C Y L H P
GTA ATC CAA AAT AAA CAA TGC TTT CAT GTC GAA TGA TGT TG
V I Q N K Q C F H V E - C -
AAC TGA TTT ATC TTA CCT GTG TAC AAT GTT ACA AGG TAA GCT
N - F I L P V Y N V T R - A
CCT GTA CGG TCA CGT CAG ACA AGT GCA AGA CTC AGA ATC TGA
P V R S R Q T S A R L R I -
ACT ACA ACG ACA GTT CTT CGA AAT GTG TTT ATT GCC AAT ATG
T T T T V L R N V F I A N M
TAT GGC TAT CTA GTT ACC TTG ACT TCA TGC TAA ATT CAG TAG
Y G Y L V T L T S C - I Q -
PolyAdenylation
__ 
Signal
ATA CCG CAA TAA AAA TTA AAC CAT TAA AAA AAA AAA 4 .
I P Q - K L N H - K K K M13
Forward
Primer
Figure 16. Nucleotide and deduced amino acid sequence of C3 clone P16A1.2/1
(Clone I) using M13 Forward Primer, indicating the position of the 3' stop codon, the
3'Untranslated Region (3'-UTR), and the polyadenylation signal.
71
Figure 17. Nucleotide and deduced amino acid sequence of internal sequence data
obtained using an antisense primer (Primer I/AS) using as template the cloned C3
insert C316A1.2/1 isolated from the cDNA library.
TCA ATG ACC ATT CCA GAC ATA TCC ATG CTG ACA GGA TTT GCT
S M T I P D I S M L T G F A
CCA GAT ATG CAA GAC CTT GAA TTG CTT CAA AAT GGA GTT GAT
P D M Q D L E L L Q N G V D
AAA TAT ATA TCA AGA TTT GAA CTA GAC AGG GCA TTA TCA GCC
K Y I S R F E L D R A L S A
CAA GGA TCA TTG ATT GTT TAT TTG GAT TCG ATT TCA CAC TTA
Q G S L I V Y L D S I S H L
GAA GAA ACT TGT TTC GGA TTT AAA GTA CAT CAA TTC TTC AAA
E E T C F G F K V H Q F F K
GTT GGA CTT ATT CAA CCA GCT TCT GTT AAA ATT TAT GAA TAT
V G L I Q P A S V K I Y E Y
TAT GAT ACA GAG AAC AGT TGC ACT AAA TTC TAT AAT GTC GAT
Y D T E N S C T K F Y N V D
GAA AGC AGT GCC ATG CTT AGC AAA ATC TGT CAA GGT 
GAA GTT
E S S A M L S K I C Q G E V
TGC AGA TGT GCA GAA GGA AGT TGT ATA TCA GTT AAG 
TTG CCT
C R C A E G S C I S V K L P
GAA CAC CAT ATC ACT TAC ATA GAT CGT GAG GAT AAA 
GCA TGT
E H H I T Y I D R E D K A 
C
GAC CAT GGA ACA GAT TAT GTT TAC AAA GTG ACA 
TTT AAC AAG
D H G T D Y V Y K V T F 
N K
AAG GAA AAA AGA GAC AGT TAC ATA TAC TAC GAA 
ATA GAG GTT
K E K R D S Y I Y Y E I 
E V
AAG TCT GTC GTA AAG CAA GGA AGC GAT GAC ATA 
TTG GAT GGA
K S V V K Q G S D D I L D G
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(figure 17 continued)
CAA GTC AGA GAA CTA ATC ATT CAT AAC AAC TGT GAA GGA ACA
Q V R E L I I H N N C E G T
TTT AAT GTG GAC TCG GAC AAT GAT TAT CTA CTG ATG GGG CAG
F N V D S D N D Y L L M G Q
GGA TCA GAC TTG TGG AGT GAT GGT AAA AGG ATC AAC TAT CTG
G S D L W S D G K R L N Y L
PRIMER I/AS
5' -TGGCACTGAACTTCTGTTGG-3'
ATT GGA GAT GGA ACC TGG TTG GAA TTT TGG CCA ACA GAA GTT
I G D G T W L E F W P T E V
CAG TGC CAA
Q C Q
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obtained for N-terminal, C-terminal, and thiolester (TE) region of nurse shark C3 clones
were aligned and compared to corresponding regions of C3, or C3-like sequences of
several vertebrate and invertebrate species (Table 4). Shark sequences showed the highest
sequence identity with Cobra (Co) C3, Human (Hu) C3 and chicken (Ch) C3 for the N-
terminal, TE region and C-terminal regions, respectively. Figure 18 displays a
diagrammatic illustration of the biologically significant regions of human C3 which
correspond to sequences that have been identified in the nurse shark from sequence data
obtained from Clones I, II, and III. Using Clustal X and Genedoc software shark
sequences were aligned with corresponding sequences of different species such as
human, lamprey, and hagfish to show residues of similar physiochemical properties
(figure 19). Significant similarity was observed. The deduced amino acid sequence of
C3 I, II, and III composite was also aligned with deduced amino acid sequence of Clone
C3A4, used as the probe to screen the library, and partial cDNA clone NsC31 which had
previously been isolated and overlaps in sequence with partial cDNA clone C3A7, and
which lacks the catalytic histidine residue (figure 20). An alignment of the N-terminal
amino acid sequence (over 222 residues) of the a-chain of C3 isolated from shark serum
with the deduced amino acid sequence of NsC3 clone show more than 95% identity
(figure 20). This suggests that partial C3 cDNA C3A4 represents the shark gene that
encodes for the functional C3 protein isolated from serum (Dodds, et al., 1998).
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Figure 20. Alignment of shark amino acid sequence deduced from C3 clones (I, II,
and III) with N-terminal amino acid sequence of shark C3 cc-chain, deduced amino
acid of nsC3A4 and nsC31. The alignment of the amino acid sequence of the N-
terminal of the alpha chain of shark C3, the C3 A4 clone, and sequence derived from
nsC31 is also shown. Positions of primers used to obtain nsC3A16 sequences are
indicated by horizontal arrows.
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V. Discussion
To comprehensively understand the evolution of a complex system such as
complement it is essential that complement genes from species representing a variety of
phyla, be cloned and sequences compared. In addition, protein sequence data of
compliment proteins also provide insight into the genetic and functional relationships.
The shark, a primitive vertebrate, holds an important phylogenetic position for study of
evolution of complement proteins, particular the thiolester proteins C3, C4, and C5 which
are believed to have arisen by gene duplication (Sottrup-Jensen, et al., 1985). The point
of divergence of these proteins from a primordial ancestor remains undetermined.
Information from the shark will be a significant contribution to determining the origin of
these proteins. Complement genes have been cloned, and complement proteins have
been isolated and characterized from several species (Sunyer et al., 1980; Nonaka, et al.,
1981; Kai, et al., 1983; Ishiguro, et al., 1992; Fritzinger, et al., 1994; Mavrodis, et al.,
1995; Smith, et al., 1996; Sunyer, et al., 1997; Al-Sharif, et al., 1998; Nakao, et al., 2000)
Characterization of shark complement genes is still in its infancy. Protein sequence data,
however, is available for shark C3 and C4 homologues (Dodds, et al., 1998; Smith,
1998). These earlier studies provided N-terminal sequence data on the a and P chain of
C3 and the a, P and y chain of C4 of the shark. The shark C3 protein was biologically
functional and contained an active thiolester as determined by its opsonic activity and
incorporation of 14C-methylamine (Dodds, et al., 1998). Previous studies on the nurse
shark, using degenerate primers and employing RT-PCR yielded two distinct
amplification products, that is, two partial cDNA clones, C3A4 and C3A7. Using gene
specific primers and performing 5'RACE PCR a 1.8 kb PCR product was obtained and
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cloned (nsC31). Sequence data obtained from nsC31 revealed that the sequence
overlapped with the partial cDNA clone C3A7. Furthermore, it was determined that the
crucial catalytic histidine at position 1126 was absent and was replaced with a tyrosine
residue (figure 20).
As the sequence of clone nsC31 overlapped with that of C3A7 rather than with
C3A4, and as the catalytic histidine (absent from nsC31) is important for the activation of
the C3 protein (since it is believed to be involved in the thiolester binding of C3 to
hydroxyl and amine groups) it seemed reasonable to assume that the partial cDNA clone
C3A4 represents the gene that encodes for the functional shark C3 protein, previously
isolated and characterized from serum. The isolation of biologically active C3 protein,
the identification of two distinct C3 clones (C3A4 and C3A7), and the identification of
NsC31 sequence lacking the critical histidine residue suggests that in the shark there are
at least two C3 genes encoding two protein molecules both expressed in the shark with
only one probably capable of being an active opsonic molecule. The C3A4 clone is
believed to represent the gene encoding the biologically active protein whereas C3A7 is
believed to represent a gene expressing a form of the protein that probably lacks an active
thiolester, however, it may still be capable of other biological activities, such as release of
anaphylatoxin fragment (C3a) upon cleavage of the a chain. While sequence
corresponding to the C3 convertase cleavage (activation) site has not been obtained
sequence data does suggest (from the conserved cysteine residues) that an active
anaphylatoxin fragment is released upon C3 activation.
In this study C3A4 was used as a probe for screening the cDNA library since we
were interested in cloning the gene encoding the biologically active thiolester containing
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C3. The construction of the cDNA library was successful resulting in 1.15 x 1016 pf
Plaque lifts were made of the amplified library and screened for the identification of
potential C3-like clones using the C3A4 plasmid as a probe by labelling it with
digoxigenin. Screening of the library with Digoxigenin labeled C3A4 probe resulted in
the identification of four positive C3-like cDNA clones: 16A1.2-1 (I), 16A1.2-2 (II),
16A1.3-1 (III), and 20A1.3-2 (IV). Three of the four clones (16A1.2-1, 16A1.2-2, and
16A1.3-1) upon analysis exhibited 98% identity to each other and were considered to
represent the same gene. Interestingly, these three similar clones came from the same
master plate number 16. The nucleic acid sequences of the three similar clones, 16A1.2-
1, 16A1.2-2, and 16A1.3-1 were translated to deduced amino acid sequence using
Genedoc software. New primers were designed using the online Primer3 program
(available at http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi) to obtain
internal sequence of the C3 clones. Newly designed primers from the 5' and 3' ends and
a degenerate primer made previously from the conserved thiolester region (CGEQNM)
were used to obtain internal sequence data.
The fourth clone which had an insert size of 4.5 kb contained many substitutions
and was significantly different in sequence from the remaining three C3 clones (figure 10
and figure 11). It is difficult to say if this clone represents a third C3 sequence (i.e.
distinct from C3A7 and nsC31), that is as yet unidentified, or if it represents mutations
that occurred in the synthesis of the library that led to this sequence being so different.
BLAST analysis of this gene sequence showed sequence similarity only with Chicken C3
and with several different reading frames. Since this sequence was so different and
because presently it has not been determined whether it represents contamination we
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decided to focus on the analysis of the 3 similar clones (I, II, and III) that originated from
plate 16.
A compilation of all sequence data obtained for the C3 clones was analyzed and
alignments made. Alignments using Genedoc software determined that there was 48.7%
identity and 66.3% similarity with human C3 over the regions compared. Lower level of
identity and similarity was found to be with the hagfish C3, which was 30% and 49.6%
respectively. A total of 754 deduced amino acid residues have been identified and the
sequence data shows overlaps with the sequence of partial C3 cDNA clone, C3A4 (which
was used to screen the library) (figure 3). Amino acid sequence for the N-terminal and
C-terminal ends, and the thiolester region respectively show 50%, 43%, and 53%
sequence identity with corresponding regions of human C3. The regions (using human
C3 numbering system) span from amino acid residue: 432 to 736, 1057 to 1224, and
1382 to 1663.
The nurse shark C3 gene sequence has characteristics in common with the human
C3 which include sequences representing several biologically active domains and
indicating molecular subunit structure. The CR3 (Complement Receptor 3) binding
domain through which binds iC3b binds to the receptor and the properdin binding site are
similar in sequence and position to those found in human C3 (figure 18 and 19). The p/a
cut site, RRRR, that is cleaved in the post-translational modification of the pro-C3
molecule into the a and P chains confirms its 2-chain structure (figure 14 and 19).
Furthermore, the presence of this cut-site shows the molecule's closer relationship to C3
rather than the a-2 macroglobulin which lacks the p/a cut site, and is a smaller molecule
consisting of a single chain. The catalytic histidine residue which previous studies have
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shown to be missing in clone NsC31 (representing C3A7), is present in the sequence
deduced from this study, indicating that the thiolester is most likely biologically
functional in the protein encoded by C3 gene corresponding to clones I, II, and III. An
active thiolester is present in the cc-chain of the C3 protein isolated from nurse shark
serum (Whitehead, et al., 1982; Fong, et al., 1990).
The total number of nucleotides sequenced from the three similar C3 clones (I, II,
and III) isolated in this study so far is 2262 bp and the size of the clones is estimated to be
approximately 3500 bp. We believe that the C3 clones isolated from the liver cDNA
library do not represent clones of the entire C3 gene since its size is speculated to be
approximately 5.0 kb, similar to that of human C3 gene. While the size of the nurse
shark C3 gene(s) is estimated to be at 5 kb, 3.5 kb of the shark C3 gene was cloned from
the cDNA library. Further studies should include the design and synthesis of new gene
specific primers based on known sequence to obtain the remaining sequence of shark C3
gene. The complete sequence of the 5'end of the nurse shark gene was not obtained from
our partial cDNA clones, however, with the 5' sequence data obtained, 5' RACE PCR
can be employed to provide additional sequence data on the 5' end sequence.
Alternatively, degenerate primers based on the protein sequence of the N-terminal of the
shark C3 P-chain may also be used to perform RACE PCR that will permit obtaining the
remainder of the C3 gene sequence, providing entire gene sequence data.
Problems encountered in this study arose when attempting to estimate the size of
the cloned inserts. The size could not be determined using PCR since optimal conditions
were not identified. When the clones were amplified in order to identify their sizes, upon
electrophoretic analysis only 2kb products were observed. This did not correlate with the
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amount of sequence data obtained which was over 2.2 kb. The reason for the
discrepancy in size estimates obtained from performing PCR may be that optimal
conditions for PCR were not provided for amplification of the large size of the clone. In
this study, as an alternative we decided to use restriction enzymes to digest the insert
from the vector and to estimate an approximate size of the clones based on restriction
fragment size, which provided more reliable size data.
In this study, the isolation of cDNA sequences has now contributed more
information on the sequence of at least one of the nurse shark C3 genes and has further
established that there are at least two separate C3 genes in the shark. Since the entire C3
gene is estimated to be 5 kb and only sequence data collectively amounting to
approximately 3 kb has been obtained, further studies dedicated to sequencing the entire
cloned C3 gene to obtain the entire 5' end region will provide the entire nucleotide and
deduced amino acid sequence. After identification of the entire gene sequence a
complete phylogenetic analysis may be done that would provide more insight into the
evolution of this pivotal protein of the complement system. The information derived
from the present study on shark C3 gene(s) is summarized in Table 5.
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Amino Acid Residues of Homologous Regions
Biologically Significant Domains of Present in the Nurse
Human C3 Shark C3 Protein *
# of C3 genes = 1 # of C3 genes = 2
1-22 leader peptide
23-667 0 chain / 432-667
668-671 P/a cut-site (RRRR) / 668-671
672-1663 a chain / 672-735
/1057-1224
/1399-1663
672-748 C3a anaphylatoxin / 672-735
955-1303 C3dg fragment / 1057-1224
955-1001 C3g fragment
1002-1303 C3d fragment / 1057-1224
1303-1321 C3f fragment
1010-1013 Thiolester domain /based on probe sequence
1424-1456 Properdin binding site / 1424-1456
1209-1271 Factor H-binding site
749-790 Factor H, B and CR1
binding site
1227-1236 CR2-binding site
1383-1403 CR-3-binding site / 1399-1403
* Based on deduced amino acid sequence data.
Table 5. Homologous regions present in the nurse shark C3 protein of biologically
significant domains of C3 in humans.
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